Synthesis and Applications of Luminescent Quantum Dots in Bioassays by Kethineedi, Venkata Ramana
University of New Orleans 
ScholarWorks@UNO 
University of New Orleans Theses and 
Dissertations Dissertations and Theses 
Fall 12-17-2011 
Synthesis and Applications of Luminescent Quantum Dots in 
Bioassays 
Venkata Ramana Kethineedi 
University of New Orleans 
Follow this and additional works at: https://scholarworks.uno.edu/td 
 Part of the Chemistry Commons 
Recommended Citation 
Kethineedi, Venkata Ramana, "Synthesis and Applications of Luminescent Quantum Dots in Bioassays" 
(2011). University of New Orleans Theses and Dissertations. 1416. 
https://scholarworks.uno.edu/td/1416 
This Dissertation-Restricted is protected by copyright and/or related rights. It has been brought to you by 
ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this Dissertation-Restricted in 
any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you 
need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative 
Commons license in the record and/or on the work itself. 
 
This Dissertation-Restricted has been accepted for inclusion in University of New Orleans Theses and Dissertations 
by an authorized administrator of ScholarWorks@UNO. For more information, please contact 
scholarworks@uno.edu. 
Synthesis and Applications of Luminescent Quantum Dots in Bioassays 
 
 
 
 
 
 
A Dissertation 
 
 
 
 
 
 
Submitted to the Graduate Faculty of the  
University of New Orleans  
in partial fulfillment of the  
requirements for the degree of 
 
 
 
 
 
 
Doctor of Philosophy  
in 
Chemistry 
 
 
 
 
 
 
by 
 
Venkata Ramana Kethineedi 
 
Bachelor of Science. Andhra University, India, 2000 
Master of Science. Andhra University, India, 2002 
 
December, 2011 
 
 
 
 
 
 ii 
Dedication 
 
I would like to dedicate this dissertation to my beloved parents Narasimha Rao Kethineedi, Late 
Samantaka Mani Kethineedi, my wife Naga Vijayalaxmi Abbaraju, and my daughter Shriya 
Kethineedi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
Acknowledgements 
 
 I would like to express my sincere gratitude to my research advisors, Dr. Zeev 
Rosenzweig and Dr. Matthew A. Tarr for their support, guidance, and encouragement during 
graduate school. Their invaluable suggestions, guidance helped me a lot throughout my duration 
here in University of New Orleans. 
I would also like to express my gratitude to my advisory committee members Dr. Richard 
B. Cole, Dr. Gabriel Caruntu, Dr. Ferdinand P. Poudeau, and Dr. John B. Wiley for their 
valuable comments and suggestions throughout my graduate research. 
 I thank Dr. Jibao He from Tulane University for the cryo-transmission electron 
microscopy analysis and Dr. Bob Cao from Dr. Weilie Zhou group for transmission electron 
microscopy analysis. I thank all my past and present research group members especially Lifang, 
Ariel and Ashley for their advice, help, and friendship.  My sincere thanks to all the faculty and 
staff in the department of chemistry and the Advanced Materials and Research Institute (AMRI) 
for their support. 
 I am thankful to my dear family and friends for always being there for me through thick 
and thin. I thank my sisters Saraswathi, Syamala, and Sailaxmi; my brother-in-laws Tagore, 
Sambashiva Rao, and Prasad; my brother Venkata Rao; my sister-in-law Padmavathi; and also 
my amazing nieces Bharathi, Srivani, Yasaswini, and Hasini. I thank my in-laws Jogeswara 
Prasad Abbaraju and Hemalatha Abbaraju. Last but not least my best buddies Durga Rao and 
Sudheer. 
 I would like to thank my financial support from DOD/DARPA grant HR0011-07-1-0032, 
NSF grant CHE-0717526, and the LA Board of Regents grant LEQSF (2007-12)-ENH-PKSFI-
PRS-04. 
 iv 
 
Table of Contents 
 
List of Figures .................................................................................................................... vi 
List of Schemes .................................................................................................................. ix 
Abstract ................................................................................................................................x 
 
Chapter 1 Introduction......................................................................................................1 
1.1 Objectives and Aims ..........................................................................................1 
1.2 Significance........................................................................................................1 
1.3 Quantum Dots ....................................................................................................2 
1.4 Liposomes ........................................................................................................10 
1.5 Phospholipases .................................................................................................12 
1.6 Myocardial Infarction ......................................................................................14 
1.7 Atherosclerosis .................................................................................................16 
1.8 References ........................................................................................................19 
 
Chapter 2 Quantum dot-liposome complexes as fluorescence resonance energy transfer 
probes to monitor phospholipase A2 enzyme activity ...................................................26 
2.1 Abstract ............................................................................................................26 
2.2 Introduction ......................................................................................................27 
2.3 Experimental Methods .....................................................................................30 
2.4 Results and Discussion ....................................................................................33 
2.5 Conclusions ......................................................................................................45 
2.6 References. .......................................................................................................46 
 
Chapter 3 Synthesis and characterization of liposome encapsulating InP/ZnS quantum dots   
3.1 Abstract ............................................................................................................49 
3.2 Introduction ......................................................................................................50 
3.3 Experimental Methods .....................................................................................52 
3.4 Results and Discussion ....................................................................................56 
3.5 Conclusions ......................................................................................................62 
3.6 References. .......................................................................................................64 
 
Chapter 4 CdSe/ZnS quantum dot based immunoassay for simultaneous detection of 
myocardial infarction biomarkers..................................................................................66 
4.1 Abstract ............................................................................................................66 
4.2 Introduction ......................................................................................................67 
4.3 Experimental Methods .....................................................................................69 
4.4 Results and Discussion ....................................................................................73 
4.5 Conclusions ......................................................................................................81 
4.6 References ........................................................................................................83 
 
 
 
 
 v 
Chapter 5 Detection of atherosclerosis biomarkers using a CdSe/ZnS quantum dot based 
fluorescence immunoassay ..............................................................................................86 
5.1 Abstract ............................................................................................................86 
5.2 Introduction ......................................................................................................87 
5.3 Experimental Methods .....................................................................................88 
5.4 Results and Discussion ....................................................................................92 
5.5 Conclusions ....................................................................................................100 
5.6 References ......................................................................................................101 
 
Chapter 6 Summary and Conclusions .........................................................................103 
6.1 Limitations and Future Studies ......................................................................108 
6.2 References ......................................................................................................110 
 
Vita ..................................................................................................................................111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
List of Figures 
 
Figure 1.1 Representation of different approaches for conjugation of quantum dots to 
biomolecules ........................................................................................................................6 
 
Figure 1.2 Biosynthesis pathways of eicosanoids from arachidonic acid.........................13 
 
Figure 2.1 (a) Emission spectra, and (b) normalized emission spectra of TOPO coated quantum 
dots in chloroform (red line) and liposome encapsulated quantum dots in PBS pH 7.2 buffer 
(green line) at 50 nM concentration of quantum dots. Digital fluorescence microscopic images of 
(c) liposome encapsulated quantum dots with an exposure time of 100 ms, and (d) liposome 
encapsulated fluorescein with an exposure time of 100 ms ...............................................34 
 
Figure 2.2 Cryo-transmission electron microscopy images of quantum dot containing liposomes 
at 50 nM (a, c), at 500 nM QD concentration (d), and liposomes without QDs (b) ..........36  
 
Figure 2.3 Emission spectra of QD-NBD-liposome based FRET probes at (a) 0, (b) 1.25, (c) 2.5, 
(d) 5, (e) 10, and (f) 25 μM of NBD C6-HPC lipid molecule concentration. λex: 375nm ..37  
 
Figure 2.4 Emission spectra of QD-NBD-liposome based FRET probes with 10 μM NBD and at 
increasing phospholipase A2 enzyme activities: (a) 0, (b) 1.5, (c) 7.5, (d) 15, (e) 37.5, and (f) 75 
U/mL. λex: 375nm ..............................................................................................................39   
 
Figure 2.5 Time dependence of QD-NBD-liposome probes with 10 μM NBD and at increasing 
phospholipase A2 enzyme activities: (a) 0, (b) 0.075, (c) 1.5, (d) 15, and (e) 75 U/mL. λex: 
375nm. The ratio Fd/Fa was normalized to (Fd/Fa)0; the ratio of Fd/Fa prior to adding 
phospholipase A2 to the QD-liposome solutions ...............................................................41 
 
Figure 2.6 Digital fluorescence microscopic images of (a) only QD-liposomes showing blue 
emission (b) QD-NBD-liposomes with 10 μM NBD showing green emission due to FRET 
between quantum dots and NBD (c) QD-NBD-liposome based probes with 10 μM NBD after 
incubating for 30 min with 75 U/mL phospholipase A2 enzyme activity ..........................42 
 
Figure 2.7 a) Time dependence of Fd/Fa at 75 U/mL of phospholipase A2 activity and increasing 
concentrations of its inhibitor MJ33. (a) control in the absence of phospholipase and inhibitor, 
(b) 50 μg/mL, (c) 1 μg/mL, (d) 0.1 μg/mL, and (e) 0 μg/mL.  b) time dependence of Fd/Fa at 75 
U/mL of phospholipase A2 activity and increasing concentrations of its inhibitor OBAA. (a) 
control in the absence of phospholipase and inhibitor, (b) 125 μg/mL, (c) 50 μg/mL, (d) 25 
μg/mL, and (e) 0 μg/mL .....................................................................................................43   
 
Figure 3.1 Normalized emission spectra of different InP/ZnS quantum dots in chloroform 
emitting from 450nm to 680nm .........................................................................................56  
 
 vii 
Figure 3.2 Transmission electron microscopic images of InP/ZnS quantum dots emitting at 556 
nm ......................................................................................................................................56 
 
Figure 3.3 (a) EDS spectrum of InP/ZnS quantum dots showing the individual peaks of In, P, 
Zn, and S elements. (b) elemental analysis showing a molar ratio of 1:0.4 for In: P in InP/ZnS 
QDs ....................................................................................................................................57 
 
Figure 3.4 (a) Emission spectra and (b) normalized emission spectra of InP/ZnS quantum dots in 
chloroform (red) and liposome encapsulated InP/ZnS quantum dots (green) in pH 7.2 PBS buffer 
at same concentration of quantum dots ..............................................................................58  
 
Figure 3.5 Particle size distributions of (a) liposomes and (b) InP/ZnS QDs containing 
liposomes. ..........................................................................................................................59 
   
Figure 3.6 (a) Emission spectra, and (b) normalized graph of liposome encapsulated quantum 
dots in PBS pH 7.2 buffer at various concentrations from 0 to 500 nM of QDs ...............60   
 
Figure 3.7 Photostability studies of lnP/ZnS quantum dots (♦), 16-mercaptohexadecanoic acid 
(MHDA) coated InP/ZnS QDs (■), and liposome encapsulated InP/ZnS quantum dots (▲) in 
PBS pH 7.2 buffer ..............................................................................................................61 
 
Figure 3.8 InP/ZnS PL intensity dependence on pH .........................................................62   
 
Figure 4.1 Fluorescence intensities of two different colored quantum dots (dotted lines) and QD-
detection antibody conjugates (continuous lines) at the same concentration of QDs........74 
 
Figure 4.2 Normalized fluorescence intensity of QD-antibody conjugates at different days.75  
 
Figure 4.3 Immobilization of capturing antibody (anti-TnT) on 96-well plate at 10 ng/mL of 
troponin T protein and 60 minutes of incubation time. λex: 400 nm ..................................77 
 
Figure 4.4 Effect of incubation time on capture of antigen on 96-well plate at 25 μg/mL of 
capture antibody and 10 ng/mL of troponin T protein concentration. λex: 400 nm ...........77 
 
Figure 4.5 a) Emission spectra of 545 nm emitting QDs in the immunocomplex at different 
concentrations of troponin T b) relationship between troponin T concentration and the 
fluorescence intensity of the QDs ......................................................................................78 
 
Figure 4.6 a) Emission spectra of 615 nm emitting QDs in the immunocomplex at different 
concentrations of troponin I b) relationship between troponin I concentration and the 
fluorescence intensity of the QDs ......................................................................................79 
 
Figure 4.7 The selectivity of the quantum dot based fluoroimmunoassay method ..........80 
 
Figure 4.8 Emission spectra of 545 nm and 615 nm emitting QDs that are bound to different 
concentrations of troponin T and troponin I respectively ................................................. 81 
 viii 
Figure 5.1 (a) Emission and (b) normalized emission spectra of TOPO coated quantum dots (red 
line) and MHDA coated quantum dots (green line) at same concentration of QDs ..........92  
 
Figure 5.2 Effect of incubation time on capture of antigen on 96-well plate at 25 μg/mL of 
capture antibodies and 1 ng/mL of IL-15 (green) and MCP-1 protein (red) concentration. λex: 
400nm ................................................................................................................................95 
 
Figure 5.3 Immobilization of capturing antibodies on 96-well plate at 1 ng/mL of IL-15 (green) 
and MCP-1 protein (red) and 60 minutes of incubation time. λex: 400 nm .......................96 
 
Figure 5.4 a) Emission spectra of 545 nm emitting QDs in the immunocomplex at different 
concentrations of IL-15 protein b) relationship between IL-15 concentration and the fluorescence 
intensity of the QDs ...........................................................................................................97 
 
Figure 5.5 a) Emission spectra of 615 nm emitting QDs in the immunocomplex at different 
concentrations of MCP-1 b) relationship between MCP-1 concentration and the fluorescence 
intensity of the QDs ...........................................................................................................97 
 
Figure 5.6 The selectivity of the quantum dot based fluoroimmunoassay method ..........98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
 
List of Schemes 
 
Scheme 1.1 Schematic representation of electronic structure of quantum dots due to quantum 
confinement..........................................................................................................................3 
 
Scheme 1.2 Schematic illustration of fluorescence resonance energy transfer principle. ...8 
 
Scheme 1.3 Schematic representation of liposome structure ............................................10 
Scheme 1.4 Schematic illustration of phospholipase cleavage sites .................................12 
Scheme 1.5 Schematic representation of troponin complex .............................................15 
 
Scheme 2.1 Schematic representation of QD-liposome based FRET probes for monitoring 
phospholipase A2 enzyme activity .....................................................................................38  
 
Scheme 3.1 Schematic illustration of light path through filter cube in an inverted fluorescence 
microscope .........................................................................................................................54 
 
Scheme 4.1 Schematic representation of QD based fluoroimmunoassay principle ..........76 
 
Scheme 5.1 Schematic representation of EDC/NHS coupling chemistry .........................93   
Scheme 5.2 Schematic representation of QD based fluoroimmunoassay principle ..........94 
 
Scheme 5.3 Schematic representation of QDs incorporated silica bead based fluoroimmunoassay 
principle .............................................................................................................................99 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
 
Abstract 
 
 
Luminescent quantum dot (QD) based probes have gained significance in the last decade 
for optical imaging of cells, tissues and in bioassays as alternatives to conventional organic 
fluorophores. The main objective of my PhD dissertation was to develop luminescent quantum 
dot based bioassays for real time monitoring of enzyme activity and simultaneous detection of 
several biomarkers. The quantum dot based bioassays developed will be potential tools in 
identification and diagnosis of several ailments that interfere with normal living conditions of 
human beings. 
In Chapter 2 new liposome encapsulated quantum dot based fluorescence resonance 
energy transfer (FRET) probes have been fabricated and characterized for monitoring the 
enzymatic activity of phospholipase A2. The probes were able to detect the enzyme activity as 
low as 0.0075 U/mL (PLA2 = 1500 U/mg) in 30 min. Further these FRET probes were also used 
to screen the inhibition efficiencies of phospholipase A2 inhibitors.  
Chapter 3 focuses on the first time synthesis and characterization of liposome 
encapsulated InP/ZnS quantum dots while preserving the integrity of the liposomes. Results from 
the experiments to assess photostability and effect of pH on the optical properties of InP/ZnS 
QD-liposomes showed greater advantages over InP/ZnS quantum dots demonstrating their utility 
as a potential tool in several biological applications such as bio imaging, bioassays and in 
immunoassays. 
Chapter 4 discusses the development of fluorescence based immunoassay for 
simultaneous detection of the cardiac biomarkers troponin T and troponin I using CdSe/ZnS 
quantum dots. The assay achieved a detection limit was 0.1 pg/mL for both biomarkers troponin 
 xi 
T and I. The method was highly specific for the both the biomarkers with no observed cross 
reactivity. The multiplex assay was able to detect two biomarkers simultaneously that will yield 
a high throughput diagnostic tool for heart attack.  
A similar method discussed as above was used in chapter 5 for the simultaneous detection 
of atherosclerosis biomarkers. The detection limits achieved in this study are comparable to the 
detection limits of the biomarkers reported so far. Incorporation of QDs in silica beads before 
conjugation to antibodies might improve detection limits that will also improve risk assessment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key words: Quantum dots, Liposomes, FRET, Phospholipase A2, QD-liposomes, Multiplexing, 
Myocardial Infarction, Troponins, Atherosclerosis, biomarkers, biosensors, immunoassay.
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Chapter 1  
 
Introduction 
 
 
1.1 Objectives and Aims 
The main objective of my PhD dissertation was to develop luminescent quantum dot 
based bioassays for real time monitoring of enzyme activity and simultaneous detection of 
several biomarkers. Luminescent quantum dots are potential alternatives to conventional organic 
fluorophores as they offer several advantages particularly broad absorption range with narrow 
symmetric emission spectrum. These advantages allows for simultaneous detection of multiple 
color quantum dots upon illumination with single light source that in turn can be used to analyze 
several analytes at the same time. My research work was specifically aimed at: i) fabrication and 
characterization of liposome encapsulated quantum dots and using them as fluorescence 
resonance energy transfer (FRET) based probes to monitor phospholipase A2 enzyme activity ii) 
synthesis and characterization of cadmium free InP/ZnS quantum dots and encapsulating them 
with liposomes iii) development of a fluorescence immunoassay for the simultaneous detection 
of heart attack biomarkers troponin T and troponin I, and iv) further use the same method to 
detect atherosclerosis biomarkers.   
1.2 Significance 
The majority of studies reported so far for monitoring the enzyme activity of 
phospholipase A2 are focused on the use of fluorophores. However the fluorophores are 
associated with several chemical and photo physical limitations like broad emission spectra, poor 
photostability, and low quantum yields. As alternatives to conventional organic fluorophores 
luminescent quantum dots have received great interest in the last decade for optical imaging of 
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cells, tissues and in bioassays. The first project was to develop liposome encapsulated quantum 
dot based FRET probes for monitoring phospholipase A2 enzyme activity and to screen the 
inhibition efficiencies of phospholipase A2 inhibitors. This method demonstrates the possibility 
to multiplex the assay in a 96 well plate and screen a large number of inhibitors simultaneously. 
Recently, focus has been shifted to the synthesis of cadmium free quantum dots due to 
cytotoxicity associated with cadmium though they are known to exhibit high quantum yields. InP 
quantum dots are more popular because they are less cytotoxic and exhibit a wide emission range 
from UV to NIR range of the electromagnetic spectrum which makes them ideal candidates for 
in vivo applications as opposed to CdSe quantum dots. For the first time InP/ZnS quantum dots 
were encapsulated with liposomes which not only enhance the optical properties of the quantum 
dots but also make them biocompatible. The next two projects were aimed at multiplexing 
quantum dots to develop fluorescence based immunoassays for simultaneous detection of 
biomarkers that play crucial role in heart attack and atherosclerosis. The ability of detecting the 
biomarkers simultaneously in a single assay reduces cost, saves time and improves the 
assessment of risk.  
1.3 Quantum Dots 
Luminescent semiconductor nanocrystalline particles or quantum dots (QDs) are 
composed of elements from groups II–VI (CdS, CdSe, CdTe, ZnO, ZnS, ZnSe), III–V (InP, 
InAs, GaP, GaN, GaAs), and IV-VI (PbS, PbSe, PbTe) of the periodic table. The nanocrystals 
usually have diameters ranging from 2-10 nm. The exciton Bohr radius defined as the average 
distance between bound electron-hole pair is confined in quantum dots in all three dimensions. 
Hence the nanoparticles have characteristics between bulk semiconductors and discrete 
molecules. This phenomenon is called the quantum-confinement effect. Quantum confinement 
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causes increased stress on the exciton that result in increased energy of the emitted photon. The 
smaller the QDs, the less room for exciton separation, and more energy is required to form the 
exciton and hence they emit at lower wavelengths (Scheme 1.1). 
 
 
 
Scheme 1.1 Schematic representation of electronic structure of quantum dots due to quantum 
confinement. 
Because of the quantum confinement effect, QDs exhibit unique optical properties that 
have several advantages over conventional fluorophores. The exceptional brightness of QDs 
comes from a combination of efficient light absorption, large extinction coefficient and high 
quantum yields up to 85%.
1
 QDs exhibit high photostability with regard to bleaching compared 
to conventional fluorophores enabling highly sensitive detection and long observation times in 
fluorescence microscopy.
2
 QDs also have narrow emission spectra and a large Stokes shift, 
which is the difference between the wavelength of absorbed and emitted light.
3
 This large shift 
allows easy separation of the fluorescence signal of QDs from excitation light source and multi-
color imaging without crosstalk between different detection channels in fluorescence 
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microscope. Additionally, QDs of different emission maxima can be excited by one single 
wavelength, which eliminates the need for numerous excitation sources in the instrumental 
setup.
4
 Quantum dots enable time-resolved detection as they have relatively long fluorescence 
lifetime (20–50 ns) that significantly increases the signal-to-background ratio relative to cell auto 
fluorescence (<5 ns).
5 
1.3.1 Synthesis of quantum dots 
Similar to traditional chemical processes colloidal semiconductor nanocrystals are 
synthesized from precursor compounds dissolved in solutions.
6
 The synthesis of 
 colloidal quantum dots is based on a three component system composed of precursors, organic 
surfactants, and solvents. During synthesis size tuning of QDs is achieved by controlling the 
relative concentrations, duration, temperature, and ligand molecules used. CdSe is a popularly 
used semiconductor material because of its tunable absorption energies throughout the visible 
region, availability of precursors for synthesis, and simple crystallization. The often used method 
to synthesize CdSe quantum dots is pyrolysis of organometallic precursors CdO, Cd(Ac)2 and 
CdCO3.
7-9
 The excited electron or hole can be trapped by surface defects, such as vacancies, local 
lattice mismatches, and dangling bonds that lead to the nonradiative recombination, which will 
result in the low quantum yield.
10
 A thin layer of high band gap semiconductor material like ZnS 
is grown on the surface of quantum dots to decrease the effect of surface defects and to protect 
surface atoms from oxidation and other chemical reactions.
11-13
 This process described as surface 
passivation improves chemical stability and photostability, increases the emission quantum yield, 
and reduces the toxicity by preventing leakage of Cd or Se to the surrounding environment.  
CdSe/ZnS quantum dots have little future in the biomedical field due to their cytotoxicity, 
though they have high fluorescence quantum yields.
14, 15
 InP quantum dots made from III-V 
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semiconductor materials are very useful because of  low toxicity and greater quantum size 
effects.
16-18
 InP/ZnS core/shell quantum dots can be synthesized to emit into the near infrared 
region that is ideal for in vivo applications. Even though InP/ZnS quantum dots are promising 
for future applications, the studies of InP/ZnS QDs are less advanced due to their more difficult 
synthetic chemistry and low quantum yields.
19
 Initially the quantum yields of InP nanocrystals 
were improved from 20–40% by HF etching.14 In 2007 Peng et al reported InP/ZnS core–shell 
quantum dot synthesis using fatty amine for which the quantum yields reached up to 40%.
20
 The 
synthesis was similar to that for CdSe quantum dots and used relatively low reaction 
temperatures below 200°C and used indium acetate and myristic acid as precursors. A one step 
and one pot method for the synthesis of highly luminescent InP with QYs of up to 30% and 
InP/ZnS QDs with QYs of up to 60% was reported by Nann et al.
21
 More recently, Reiss et al 
synthesized InP/ZnS QDs in a single step with quantum yield up to 70%.
22
 
1.3.2 Bioconjugation of quantum dots  
The high quality quantum dots synthesized in organic solvents are insoluble in water, do 
not have functional groups for bioconjugation and are thus non-biocompatible. In order to make 
them biocompatible the hydrophobic coating ligands of luminescent quantum dots must be 
replaced with bifunctional hydrophilic capping ligands or must be further coated with an 
amphiphilic layer to impart water solubility and potential bioconjugation sites (Figure 1.1). 
These treatments will facilitate their applications in biological systems. Various methods for the 
improvement of quantum dot biocompatility and stability have been developed during the past 
few years. One of the most commonly used methods is ligand exchange that involves the 
replacement of hydrophobic ligands with bifunctional ligands in which one end binds to the 
inorganic QD surface and the other end provides hydrophilicity. The hydrophobic capping 
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ligands are often exchanged with thiol functionalized compounds such as mercaptoalkanoic 
acids.
23-27
 The thiol binding to the ZnS surface is not very strong resulting quantum dots 
aggregation over time.
28
 This instability is the limitation of capping quantum dots with thiol 
containing ligands.  
 
Figure 1.1 Representation of different approaches for conjugation of quantum dots to 
biomolecules. 
Another method is silica encapsulation, which involves the growth of a silica layer on the 
surface of the quantum dots. Functional groups –SH and –NH2 on the surface of organosilane 
molecules enable bioconjugation.
29, 30
 However, the method is very laborious, difficult to 
reproduce, and the silica layer may be hydrolyzed.
31
 Yet another method is coating QDs with an 
amphiphilic polymer and phospholipids. This approach is achieved by forming the layer on the 
QD surface via hydrophobic interactions with the hydrophobic ligands.
32
 The polymer has a 
hydrophilic exterior that makes the quantum dots soluble in aqueous solutions. However, this 
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method limits many biological applications such as FRET measurements and endocytosis since 
the size of the coated quantum dots becomes much larger.
31
 In addition to the above mentioned 
methods there are several methods for developing water-soluble, biocompatible quantum dots. 
Synthesizing high quality water soluble and stable quantum dots still remains an important area 
of research in quantum dot based nanobiotechnology. 
1.3.3 Biological application of quantum dots 
Quantum dots are new generation of fluorescent probes that are promising tools in 
biological applications as an alternative to commonly used organic fluorophores due to their 
unique optical and chemical properties. Water soluble quantum dots have been extensively used 
in protein assays,
33-35
 hybridization assays,
36-38
 and fluorescence resonance energy transfer 
(FRET) based bioassays.
39-41
 They have also been used as labels for in vitro
42-44
 and in vivo
45-47 
imaging applications.
  
 
1.3.3.1 Quantum dots as FRET donors 
Fluorescence resonance energy transfer (FRET) is a non radiative energy transfer from 
the donor in excited state (D) to an acceptor (A) (Scheme 1.2). The energy transfer is a result of 
long-range dipole-dipole interactions between the donor and acceptor.
48, 49
 Thus the fluorescence 
intensity and lifetime of the donor is decreased and the acceptor fluorescence intensity is 
increased. The rate of energy transfer depends on the following three important conditions: (i) 
spectral overlap between the absorption spectrum of the acceptor and the fluorescence emission 
spectrum of the donor; (ii) close proximity between the donor and acceptor molecules (typically 
0.1-10 nm); and (iii) approximately parallel donor and acceptor transition dipole orientations. 
FRET with optical microscopy, is a powerful photo-physical technique because of its high 
sensitivity to changes in distance and relative dipole orientations between donor and acceptor. 
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FRET has been widely used to study protein-protein interactions, diffusion dynamics, protein 
conformational changes, and detecting nucleic acids and peptides.
50-52
 
Conventional fluorescent organic molecules have been extensively used as FRET pairs 
due to their small size, compatibility with covalent coupling, and relatively large detectable 
optical signal. However, organic fluorophores as FRET probes have narrow absorption spectra of 
the acceptors, broad emission spectra of the donors, and low photo bleaching thresholds. 
Quantum dots provide a potential solution to the above problems. QDs have been investigated as 
FRET donors in place of traditional organic dyes because of their high photostability and unique 
spectral properties.
53-55
  
 
Scheme 1.2 Schematic illustration of fluorescence resonance energy transfer principle. 
Several research groups reported FRET between quantum dots and organic dyes.
56-58 
Willard et al developed quantum dots as FRET donors in a protein-protein binding assay.
59
 
Quantum dots were conjugated to bovine serum albumin as FRET donors and 
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tetramethylrhodamine was bound to the protein as the FRET acceptors. In 2003, Medinta et al 
first reported quantum dots based self-assembled nanoscale FRET biosensors for maltose 
detection by coating CdSe/ZnS quantum dots with maltose binding protein molecules.
60
 Since 
then, quantum dots based FRET biosensors have been reported to detect TNT,
61
 toxins,
62
 β-
lactamase,
63 
collagenase,
64
 DNA,
65
 RNA,
66
 and protein.
67
   
1.3.3.2 Quantum dots in immunoassays 
Immunolabeling is one of the widely explored bioapplications of quantum dots. QDs in 
this category are more advanced than organic fluorophores due to their unique features like 
photostability and multiplexing capability. The majority of the studies reported so far 
demonstrated the use of QDs in target detection of various cancer markers within cells.
68-70
 
These markers have been of pathological interest because they were either associated with 
transformations or metastasis and were indicative of both the cancer and its progress. Other uses 
include monitoring intracellular viruses, typing of blood cell antigens and visualization of drug 
therapy effects in cellular metabolism.
71, 72
 Wilson et al used magnetic microspheres encoded 
with three different quantum dots for the multiplexed detection of three different explosives.
73
 
Gao et al described the use of tri-block copolymer coated quantum dots to perform in vivo 
targeting and imaging of human prostate cancer cells.
74
 In 2007 Yezhelyev et al used a hetero-
bifunctional cross linker to covalently attach multicolored QDs to antibodies that were used to 
perform in situ molecular profiling of five different breast cancer biomarkers.
75 
Zhang et al in 
2008, synthesized high quality multicolor amphiphilic copolymer coated 
CdSe/CdS/Cd0.5Zn0.5S/ZnS QDs and used them for detecting human and rabbit antigens.
76
 
Recently, Rauf et al developed QD bar coded magnetic microspheres based multiplexed 
immunoassays via a layer-by-layer technique utilizing unique streptavidin/biotin interaction.
77
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1.4 Liposomes 
Liposomes are spherical artificial phospholipid vesicles that are used as models for 
artificial cells, making them versatile tools in biology, biochemistry and medicine. Liposomes 
form spontaneously when introduced into aqueous media. Similar to cell membranes, the 
spherical phospholipids self-assemble to form a bilayer in which the phospholipid head groups 
point toward the internal and external aqueous phases of the vesicles and the tails are enclosed in 
a hydrophobic region. The liposomes are classified according to the compartmentalization of 
aqueous regions between bilayers. In unilamellar liposomes, the aqueous compartment is 
separated from the external solution by only one membranal bilayer. Unilamellar liposomes are 
further classified based on the size. Small unilamellar liposomes (SUV) have 100 nm average 
diameters while large unilamellar liposomes (LUV) have a maximal size of up to 10 m. 
Multilamellar liposomes, consist of more than one bilayer each separated by an aqueous 
compartment. The size, lamellarity (unilamellar or multilamellar) and lipid composition of the 
bilayers influence many of the important properties like the fluidity, permeability, stability and 
structure that can be controlled and customized to serve specific needs. 
 
Scheme 1.3 Schematic representation of liposome structure. 
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There are numerous approaches to prepare liposomes such as the injection method, the 
dehydration/rehydration method, and the freeze thaw method. The synthesized liposomes are 
characterized by light scattering, electronic or atomic force microscopy, and capillary 
electrophoresis. Static and dynamic light scattering measurements are used to characterize the 
size, size distribution, and shape of vesicles. The morphology of liposomes can be further 
characterized by transmission electron microscopy (TEM) and atomic force microscopy 
(AFM).
78
 The light scattering techniques provide average values of the physical characteristics of 
liposome suspensions, while the TEM and AFM approaches provide information on individual 
liposomes that may or may not represent the entire liposome population. Capillary 
electrophoresis can also be used to obtain qualitative and quantitative information about the size 
to charge ratio of liposomes as they are very stable under high electric fields.
79, 80
  
Liposomes offer exceptional engineering ability due to their physicochemical 
characteristics such as vesicle size, structure and surface versatility that can be modified with 
established methods. They have been used to encapsulate and deliver oral vaccines as well as 
anti cancer, anti inflammatory and hormonal drugs.
81, 82 
Liposomes can entrap large amounts of 
fluorescent nanoparticles while providing high biocompatibility, and thus enhancing the 
effectiveness of nanoparticles for detection in vivo and in vitro.
83
 Recently, fabrication of QD-
liposome vesicles gained importance as promising tools in nano-biotechnology. QDs have been 
incorporated into phospholipid liposomes making them biocompatible while retaining 
photoluminescence. The liposome quantum dot complexes have been applied as fluorescent 
markers in immunoassays
84
 and also to deliver QDs into cytosol of oncogenic brain cells via 
lipid mediated fusion with the cell membrane.
85
 QD-liposomes have also been used for tumor 
 12 
cell-targeting, imaging, and drug delivery functions in human epidermal growth factor receptor 2 
over expressing tumor cells via receptor-mediated endocytosis.
86 
1.5 Phospholipases
 
Phospholipases are lipolytic enzymes that catalyze the hydrolysis of membrane 
phospholipids. Their classification is based on cleavage of the bond in phospholipids (scheme 
1.4). Phospholipase A1 and A2 selectively remove fatty acids from the SN1 and SN2 positions 
respectively. Phospholipase B cleaves both SN1 and SN2 acyl bonds. Phospholipase C cleaves 
the bond between glycerol and phosphate and phospholipase D hydrolyzes the amino alcohol 
moiety from a phospholipid. 
 
Scheme 1.4 Schematic illustration of phospholipase cleavage sites. 
Phospholipase A2 (PLA2) are small proteins (ca. 14 kDa) containing multiple disulfide 
bridges. The water-soluble forms of these extracellular enzymes are the most thoroughly studied 
and have been used as model systems for the less tractable, membrane-bound forms, as well as 
for the study of enzyme catalysis at lipid/water interfaces.
87
 PLA2 can be found in membrane-
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associated and soluble forms in almost all cell types, where they are believed to play an 
important role in the normal biosynthesis and turnover of membrane phospholipids,
88, 89
 cellular 
signaling,
90
 and protection of membranes from peroxidation damage.
91
 In addition, PLA2 
enzymes have also been associated with the pathogenesis of numerous clinical inflammatory 
processes.
92, 93
 PLA2 catalyzes the hydrolysis of the SN2 fatty acyl ester bond of phospholipids to 
yield arachidonic acid and lysophospholipid.  
 
 
 
 
 
 
          
 
 
 
 
Figure 1.2 Biosynthesis pathways of eicosanoids from arachidonic acid. 
 
Arachidonic acid is converted by the cyclo-oxygenase (COX-1 or -2) pathway to produce 
a variety of prostaglandins and thromboxanes (Figure 1.2). Specific prostaglandins can cause 
constriction or dilation in vascular smooth muscle cells, cause aggregation or disaggregation of 
platelets, control hormone regulation, control cell growth, decrease intraocular pressure, decrease 
micro vascular permeability and cause platelet aggregation that can influence the course of 
inflammatory episodes.
94
 Thromboxane is a vasoconstrictor, a potent hypertensive agent, and 
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facilitates platelet aggregation. Leukotrienes play a powerful role in asthma, bronchoconstriction, 
and other inflammatory responses. Also they play a role in cardiovascular and neuropsychiatric 
illnesses. Lysophospholipids, another product of PLA2 enzymatic activity, produce platelet 
activating factor, which causes a drop in blood pressure and reduced volume of blood pumped by 
the heart. These effects can lead to shock and possibly death. Thus the inhibition of 
phospholipase A2 which in turn blocks the formation of arachidonic acid is of great significance. 
1.6 Myocardial Infarction.  
Myocardial infarction (MI) or heart attack is the interruption of blood supply to some 
parts of the heart muscles, causing cell death. This phenomenon occurs due the rupture of 
a vulnerable atherosclerotic plaque, which is a collection of unstable lipids and white blood 
cells especially macrophages in the wall of a coronary artery that leads to blockage. The 
restriction in blood supply and shortage in oxygen can lead to damage or death (infarction) of 
heart muscle tissue (myocardium) if left untreated for a long period of time. According to the 
World Health Organization (WHO), heart attack is the leading cause of death for both men and 
women worldwide. Every 34 seconds someone in the United States has a heart attack.
95
  
The diagnosis of MI has been based on the “two out of three” criteria over several 
decades as defined by WHO, including typical chest pain symptoms that last for more than 20 
minutes, changes in serial electrocardiogram, and increase in the serum level of creatine kinase-
MB and troponins.
96
 The WHO criteria have been refined in 2000 and recently in 2007 that gave 
more importance to cardiac biomarkers especially troponins.
97
 According to this new criteria 
cardiac troponin elevation accompanied by any of the typical symptoms are the diagnosis for 
heart attack. Troponin is a complex of three regulatory muscle proteins troponin T (TnT), 
troponin I (TnI), and troponin C (TnC) that play crucial role in muscle contraction. Troponin I 
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binds to actin, troponin T binds to tropomyosin, and the third troponin C binds to calcium ions 
(Scheme 1.5). When calcium ions bind to troponin C, the troponin changes shape, forcing 
tropomyosin away from the actin filaments. This causes myosin cross-bridges to attach to actin, 
and thus enable contractions.
98
 In the absence of calcium troponin C does not undergo 
conformational change and therefore muscles remain intact.  
       
 
Scheme 1.5 Schematic representation of Troponin complex.  
Cardiac and skeletal muscles contain both troponin T and I, however the amino acid 
sequences of the proteins are different.
99
 Troponin C is shared by cardiac and skeletal muscles 
and therefore does not have cardiac specificity and is not used in assays for the diagnosis of 
cardiac injury. Under normal conditions troponin T and I levels are very low but the 
concentrations rise immediately following the heart attack. The release kinetics for both TnT and 
TnI are similar and release within 4-13 hr following myocardial damage.
100
 Currently, several 
immunoassay methods are available commercially for the detection of troponin I and troponin T 
separately, most of them are based on ELISA and some of them based on fluoimmunoassay 
technique.
101-105
 However, the current detection limits of troponin assays do not allow 
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demonstration of normal cardiac troponin in healthy controls.
106
 Further lower detection limits 
with improved assay sensitivity and precision would improve risk assessment. 
1.7 Atherosclerosis 
Atherosclerosis is a condition that results in accumulation of fatty materials such as 
cholesterol causing the artery wall to increase in thickness. Atherosclerosis develops from low-
density lipoproteins (LDL) that are oxidized by reactive oxygen species (ROS). LDL is in 
globular shape that carries cholesterol from the liver to cells. A number of reactions occur to 
repair the damage when oxidized LDL comes in contact with an artery wall, one such reaction is 
the response of the body's immune system by sending specialized white blood cells 
(macrophages and T-lymphocytes) to absorb the oxidized-LDL forming the specialized foam 
cells. Accumulation of foam cells in the artery wall leads to formation of plaque, which can 
constrict the blood vessels diameter. Although plaque can block blood flow, arteries respond to 
this blockage by increasing their size. Consequently, plaque formation is not necessarily harmful. 
However, some plaques become unstable and can rupture. Upon rupture, clot forming 
compounds can be released, resulting in acute blockage of blood flow that can cause localized 
tissue death. When such an event occurs in the heart, MI results. Blockages occurring in the 
brain result in stroke. Plaque can also harden through calcification, resulting in reduction of the 
blood flow and an increase in blood pressure. 
Atherosclerosis is a chronic disease characterized by arterial lesions despite the lack of 
any symptoms for many years.
107 
Atherosclerotic lesions or plaques are categorized as stable and 
unstable.
108
 Stable atherosclerotic plaques are asymptomatic and are rich in extracellular matrix 
and smooth muscle cells while unstable plaques are rich in macrophages, and foam cells and are 
usually weak and prone to rupture. For a long time the diagnosis of cardiovascular disease in 
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humans was based on severe narrowing, stenosis that was detected using angiography and stress 
testing. Angiography is a conventional method of testing accumulated lipid-containing plaques in 
the artery or atheroma, which shows motion or still images of inner space of the artery but does 
not show atheroma within the arterial wall. All these methods are useful for diagnosis at later 
stages of atheroma i.e. narrowing of arterial walls but do not help early detection. The current 
most sensitive method, intravascular ultrasound detects and measures atheroma allowing 
complete and accurate assessment than angiography within living individuals. Due to limitation 
in cost and the method being body invasive, it is not used until after atheroma begins forming. 
On the other hand CT scans have been the most effective method for detecting calcification 
present in plaque however atheroma has to be advanced enough to have relatively large areas of 
calcification within them.  
Recent research efforts have repeatedly shown the use of biomarkers involved in different 
stages of atherosclerosis like molecular proinflammatory biomarkers, plaque destabilization and 
plaque rupture biomarkers to predict future cardiovascular occurrences not only in healthy 
individuals, but also in patients with acute coronary syndrome.
109
 Therefore testing patients for 
several of these markers will provide important information useful for predicting future 
occurrence of atherosclerosis. Thus my fourth project aims at detecting the three biomarkers 
monocyte chemoattractant protein-1 (MCP-1), interleukin 15 (IL-15), and interleukin 18 (IL-18) 
that play a significant role in two important stages of atherosclerosis, fatty streaks and plaque 
destabilization. MCP-1 is an important chemokine that is involved in regulated migration and 
infiltration of monocytes/macrophages whose effects are mainly mediated through β-chemokine 
receptors 2. In response to various cytokines, growth factors, and oxLDL
110
 monocytes express 
MCP-1 and thus increase expression of MCP-1 in atherosclerotic lesions, particularly in 
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macrophage-rich areas.
111
 In animal models, the extent of atherosclerosis and macrophage 
infiltration into the atherosclerotic lesion is evaluated based on the expression of MCP-1.
112 
Interleukin 15 is another biomarker associated with atherosclerosis, it is a cytokine with 
structural similarity to IL-2. IL-15 is found in high levels in plasma of patients with coronary 
artery disease.
113 
The expression of IL-15 is found exclusively in fibrolipid and lipid-rich plaques 
in complex foam cells.
114 
The up regulation of IL-15 in atherosclerotic lesions, stimulates T 
lymphocytes.
115  
IL-18, is another biomarker and proinflammatory cytokine that is widely 
expressed in various cell types. IL-18 enhances the expression of matrix metalloproteases 
(MMPs)
116-118
 along with interferon eliciting helper T cell (Th1) immune response and these two 
abilities of IL-18 characterize it as a crucial and potent mediator of atherosclerotic plaque 
destabilization. In human atherosclerotic plaques, increased expression of IL-18 is seen in lesions 
prone to rupture, and is localized mainly in plaque macrophages.
119
 In animal models, inhibition 
of IL-18 by IL-18 binding protein reduced atherosclerotic plaque development and progression 
supporting a proatherogenic role of IL-18.
120
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Chapter 2 
 
 
Quantum dot-liposome complexes as fluorescence resonance energy 
transfer probes to monitor phospholipase A2 enzyme activity  
 
 
2.1 Abstract  
In the current chapter new liposome encapsulated quantum dot (QD) based fluorescence 
resonance energy transfer (FRET) probes for monitoring the enzymatic activity of phospholipase 
A2 have been fabricated and characterized.  Luminescent CdSe/ZnS quantum dots in the lipid 
bilayer acted as donor and the lipid bound membrane dye NBD acted as acceptor. As the 
quantum dots were not attached covalently to the phospholipids they did not affect the enzyme 
activity of phospholipase A2. The addition of phospholipase A2 to QD-liposomes demonstrated 
changes in FRET signals due to cleavage of the SN2-acyl bond and release of NBD fluorophores 
from the membrane. The changes in FRET signals were found to be dependent on phospholipase 
A2 enzyme activity. The probes were able to detect enzyme activity as low as 0.0075 U/mL 
(PLA2 = 1500 U/mg) in 30 min. The FRET format thus enables real time monitoring of the 
enzyme activity. Further these FRET probes were also used to screen the inhibition efficiencies 
of phospholipase A2 inhibitors. It is also possible to multiplex the assay in a 96 well plate and 
screen large number of inhibitors simultaneously. Thus, the developed in vitro bioassay is 
sensitive, reliable and can be easily performed to provide valuable information about 
phospholipase A2 and its inhibitors for both medical and pharmacological fields. 
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2.2 Introduction 
Luminescent quantum dot (QD) based probes have been effectively utilized in the last 
decade for optical imaging of cells and tissues and in bioassays as alternatives to conventional 
organic flurophores.
1,2
 QDs have unique size-dependent chemical and physical properties 
offering advantages like brightness, greater photostability, broad excitation wavelength range, 
and size-tunable narrow, and symmetric emission spectra ranging from 400 to 2000 nm.
3-8
 
However, quantum dot applications in bio-medical and clinical fields have been limited by the 
disadvantage of QDs being capped with hydrophobic coating ligands.
9,10
 To overcome this 
limitation, focus has been made on several synthetic strategies over the past several years to 
make QDs water soluble and biocompatible. The attempts towards solubilization involved the 
exchange of the hydrophobic surface ligands with hydrophilic thiol containing molecules like 
mercaptoalkanoic acids.
4,11-13
 Some studies used other exchange ligands like dendrons,
14 
peptides,
15,16
 silica,
17
 block copolymers
18, 19
 or encapsulated QDs in water miscible phospholipid 
micelles.
20
 
Recently, fabrication of QD-liposome vesicles gained importance as a promising tool in 
nano-biotechnology. QDs have been incorporated into phospholipid liposomes making them 
biocompatible while retaining photoluminescence. Liposomes are concentric bilayered vesicles 
consisting of a hydrophobic phospholipid bilayer surrounding a hydrophilic aqueous phase. 
Liposomes offer exceptional engineering ability due to their physicochemical characteristics 
such as vesicle size, structure and surface versatility that can easily be modified with established 
methods. Liposomes can entrap large amount of fluorescent nanoparticles providing high 
biocompatibility, thus they enhance the effectiveness of nanoparticles for detection in vivo and in 
vitro.
21
 They have been used to encapsulate and deliver oral vaccines as well as anti cancer, anti 
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inflammatory and hormonal drugs.
22-24
 Liposome quantum dot complexes have been applied as 
fluorescent markers in immunoassays
25
 and also to deliver QDs into cytosol of oncogenic brain 
cells via lipid mediated fusion with the cell membrane.
26
 Further, QD-liposomes were also used 
for tumor cell-targeting, imaging, and drug delivery functions in human epidermal growth factor 
receptor 2-overexpressing tumor cells via receptor-mediated endocytosis.
27
  
Phospholipase A2 (EC 3.1.1.4) is a family of lipolytic extracellular enzymes that are 
relatively small proteins (ca. 14 kDa) containing multiple disulfide bridges. Phospholipase A2 
can be found in membrane-associated and soluble forms in almost all cell types, where they are 
believed to play an important role in the normal biosynthesis
28-31
 and pathogenesis of various 
inflammatory processes.
32, 33
 Phospholipase A2 catalyzes the hydrolysis of the SN2 fatty acyl 
ester bond of phospholipids to yield arachidonic acid, and a lysophospholipid. Arachidonic acid 
produces leukotrienes by the lipooxygenase pathway that play powerful role in asthama, 
broncho-constriction, cardiovascular and neuropsychiatric illnesses. Lysophospholipids, another 
product of phospholipase A2 enzymatic activity, produce platelet activating factor which causes a 
drop in blood pressure and reduced pumping of blood by the heart, which leads to shock and 
potentially death. Thus the measurement of phospholipase A2 enzyme activity can be of major 
medical importance in drug discovery. 
Phospholipase activity was monitored using traditional methods including titrimetry, 
colorimetry, fluorometry and radiometry.
34
 Most of the methods are limited in terms of 
sensitivity with the exception of fluorometry and radiometry. Radiometric methods are most 
sensitive and most widely used but they are expensive, hazardous, laborious, and impractical 
when dealing with large scale samples. Many of the initial fluorescence assays were 
discontinuous and require phase separations to separate substrate and products. Wilton et al have 
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described a continuous fluorescence displacement assay for PLA2 that involves monitoring the 
loss of fluorescence when the fatty acid probe 11-(dansylamino)undecanoic acid is displaced 
from liver fatty-acid-binding protein as a result of PLA2 activity.
35
 The assay detected enzyme 
activity down to ~10 pmol/mL. Prestwich et al reported a fluorogenic assay for the detection of 
PLA2 activity in real time using FRET with substrates having SN1-acyl chain labeled with 
Dabcyl and SN2-acyl labeled with BODIPY fluorophore.
36
 Perez-Gilabert et al described a 
spectrophotometric assay for the continuous and indirect measurement of PLA2 activity.
37
 The 
activity of PLA2 is measured by the increase in absorbance at 234 nm due to the formation of 
hydrogen peroxide from linoleic acid released from hydrolyses of dilinoleoyl 
phosphatidylcholine. Recently, a fluorescence assay for PLA2 was reported by Whitten et al 
where cationic poly(phenyleneethynylene) PPE derivatives physically adsorbed onto solid 
nonporous borosilicate microspheres were subsequently coated with 1,2-dimyristoyl-sn-glycero-
3-[phospho-rac-(1-glycerol)] (DMPG).
38 
The lipid bilayer acts as a substrate for PLA2 and also 
shields the fluorescence of PPE from quenching by 9,10-anthraquinone-2,6-disulfonic acid 
(AQS). The amplified quenching of the polymer fluorescence by AQS is restored, as the DMPG 
is digested by PLA2. 
Many research labs including ours have recently developed quantum dot based 
fluorescence resonance energy transfer based assays.
39-44
 Chang et al developed solution based 
FRET assays using QDs as donors and gold nanoparticles as acceptors for proteolytic activity 
measurements.
44
 Shi et al from our lab have covalently linked molecular fluorescent acceptors to 
the surface of single quantum dot and used the FRET probes for real-time monitoring of protease 
activity in solution.
42
 Most of the developed quantum dot based FRET assays were focused on 
measuring the proteolytic activity. In the current study, a quantum dot based FRET assay was 
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employed for lipase activity measurements. The quantum dot encapsulated liposome based 
FRET probes were synthesized and characterized to monitor the enzymatic activity of 
phospholipase A2. The phospholipid bilayer in QD encapsulated liposomes were also labeled 
with acyl NBD fluorophores. The addition of phospholipase A2 to QD-liposomes showed 
changes in FRET signals due to cleavage of SN2-acyl bond and release of NBD fluorophores 
from the membrane (scheme 2.1). These changes in FRET signals were found to be 
phospholipase A2 concentration dependent. Further the FRET probes were also used to screen the 
inhibition efficiencies of phospholipase A2 inhibitors. This method demonstrates the possibility 
to multiplex the assay in a 96 well plate and screen a large number of inhibitors simultaneously.  
2.3 Experimental Methods 
2.3.1 Materials and reagents. Technical grade (90%) trioctylphosphine oxide (TOPO), 
technical grade (90%) trioctylphosphine (TOP), cadmium oxide (99.99%), selenium powder 
(99.5%), lauric acid (98%), technical grade (90%) hexadecylamine (HDA), diethyl zinc (Zn(Et)2) 
solution 1.0 M in heptane, hexamethyldisilathiane ((TMS)2S), methanol anhydrous (99.8%), 
chloroform (99.5%), cholesterol, and phospholipase A2  from honey bee venom were purchased 
from Sigma Aldrich. 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1,2-dioleoyl-sn-
glycero-3-phosphoglycerol (DOPG) were purchased from Avanti Polar Lipids. N-(fluorescein-5-
thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine triethyl ammonium salt 
(DHPE-fluorescein), 2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoyl-
sn-glycero-3-phosphocholine (NBD C6-HPC) were purchased from Invitrogen. All reagents were 
used as received without further purification. 
2.3.2 Synthesis of TOPO capped luminescent quantum dots. TOPO-capped CdSe/ZnS 
quantum dots were prepared following a method first proposed by Peng
6 
with a slight 
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modification.
45
 Briefly, 12-13 mg of cadmium oxide and 160-180 mg of lauric acid were mixed 
under nitrogen atmosphere. The mixture was heated in a 100 mL three neck flask to slightly 
above 200°C to fully dissolve the cadmium oxide (clear solution).  Then, 2 g of TOPO and 2 g 
HDA were added to the solution with constant stirring. Temperature was raised to 280°C before 
being cooled down slowly. Upon reaching the desirable temperature 80 mg selenium powder 
dissolved in 2 mL solution of TOP was rapidly injected into the solution under vigorous stirring. 
For shell coating, a 2 mL TOP solution containing 250 μL (TMS)2S and 1 mL Zn(Et)2 was 
injected drop-wise into the solution. The reaction mixture was kept at 180°C for one hour before 
it was cooled to room temperature, washed three times with methanol, centrifuged at 4000 rpm 
for 10 minutes each, and redispersed in chloroform. The concentration of this solution was found 
to be 1 μM. The solution was stored at room temperature.   
2.3.3 Encapsulation of quantum dots with liposomes. A 20 mM lipid stock solution was 
prepared with 1:1:0.4 molar ratios of DOPC, DOPG, and cholesterol in chloroform. The 
phospholipid stock solution was stored in a sealed vial at -10°C until use. A 100 μL aliquot of 
the lipid stock solution was added to 75 μL of 1 μM TOPO coated quantum dots and dried under 
nitrogen in a glass vial until all the chloroform was removed.  A thin film formed at the bottom 
of the glass tubes. 1 mL of 10 mM pH 7.4 PBS buffer was added to the above formed thin film 
followed by sonication for 10 minutes and vortexing for 2 minutes. Unilamellar liposomes 
containing quantum dots in the membrane were thus formed. 
2.3.4 Fabrication of QD-NBD-liposome based FRET probes.  A 100 μL aliquot of 20 mM 
lipid stock solution was added to 75 μL of 1 μM TOPO coated quantum dots and then mixed 
with varying volumes 0, 25, 50, 100, 200, and 500 μL of 100 μM NBD C6-HPC lipid molecules 
dissolved in chloroform. These mixtures were further dried under nitrogen in a glass vial until all 
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the chloroform was removed.  A thin film formed at the bottom of the glass tubes. 1 mL of 10 
mM pH 7.4 PBS buffer was added to the above formed thin film followed by sonication for 10 
minutes and vortexing for 2 minutes. The corresponding NBD concentrations in the fabricated 
QD-NBD-liposome based FRET probes are 0, 2.5, 5, 10, 20, and 50 μM respectively. Another 
two fold dilution was performed on these samples to measure changes in FRET signals. 
2.3.5 Enzyme activity and inhibition assays.  A 100 μL aliquot of QD-NBD-liposome FRET 
based probes with 20 μM NBD was dissolved in PBS buffer pH 8.0, following which varying 
volumes of 0.5 mg/mL phospholipase A2 in PBS buffer containing 1 mM of CaCl2 were added to 
make a final volume of 200 μL. Time-dependent spectral measurements were carried out 
following the addition of phospholipase A2 using a fluorescence spectrometer or a digital 
fluorescence spectral imaging system. Inhibition assays were monitored using fluorescence 
spectroscopy. To carry out the inhibition assays, 50 μL of 100 μg/mL phospholipase A2 was 
added to various concentrations of inhibitors to a total volume of 100 μL. Following 30-min 
incubation, 100 μL of 75 nM QD-liposome FRET-based probes was added to the mixture and 
FRET measurements were carried out to monitor to enzymatic reaction. 
2.3.6 Fluorescence spectroscopy measurements. Excitation and emission spectra were 
measured using a spectrofluorometer (Perkin Elmer), equipped with a 75-W continuous Xenon 
arc lamp as a light source. The samples with DHPE-fluorescein were excited at 480 nm. For the 
FRET assay all the samples were excited at minimum absorption wavelength of 375 nm to 
reduce interference from direct excitation of NBD molecules. All other samples were excited at 
400 nm. Emission scans were measured from 425-700 nm. 
2.3.7 Digital fluorescence imaging microscopy. Luminescence images were obtained using a 
digital inverted fluorescence microscope (Olympus IX71) equipped with a 100 W mercury lamp 
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as a light source. The fluorescence images were collected via a 20 X microscope objective with 
numerical aperture = 0.5. A filter cube containing a 380±20 nm band-pass excitation filter, a 425 
nm dichroic mirror, and a 450 nm long pass emission filter was used to ensure spectral imaging 
purity.  Digital point controller (DP72) was used for digital imaging. An exposure time of 100 
ms was typically used to acquire the fluorescence images of QD based probes.  
2.3.8 Cryo-transmission electron microscopy measurements. Sample preparation for cryo-
transmission electron microscopy was carried out in a temperature and humidity controlled 
chamber. A specimen grid was dipped into a suspension and withdrawn, and excess liquid was 
blotted away. Thin films were formed between the bars of the grids. To vitrify these thin films, 
the grid was shot into melting ethane. The grids with vitrified thin films were analyzed with a 
JEM2010 high resolution transmission electron microscope (JEOL, Tokyo) at -170°C using a 
Gatan-626 cryo-specimen holder and cryotransfer system (Gatan, Warrendale, PA). The 
micrographs were collected at 120 kV. This microscope is equipped with a Gatan 2048- 2048 
CCD camera and a Gatan energy filter. 
2.4 Results and Discussion 
2.4.1 Characterization of QD-liposomes. Luminescent CdSe/ZnS quantum dots were 
successfully encapsulated into DOPC, DOPG, Chol (1:1:0.4) liposomal bilayer membranes 
rendering the quantum dots water soluble. During the encapsulation process the hydrophobic 
coating on the surface of QDs interacts with hydrophobic regions of liposomes via hydrophobic 
interactions while the hydrophilic region of liposome is exposed to the water phase.  
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Figure 2.1 (a) Emission spectra, and (b) normalized emission spectra of TOPO coated quantum 
dots in chloroform (red line) and liposome encapsulated quantum dots in PBS pH 7.2 buffer 
(green line) at 50 nM concentration of quantum dots. Digital fluorescence microscopic images of 
(c) liposome encapsulated quantum dots with exposure time of 100 ms, and (d) liposome 
encapsulated fluorescein with exposure time of 100 ms. 
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The liposome encapsulated quantum dots were characterized for optical properties using 
a spectrofluorometer and digital fluorescence imaging microscopy.  Figure 2.1 (a, b) are the 
emission and normalized spectra of TOPO coated quantum dots and liposome encapsulated 
quantum dots respectively, at the same concentration of quantum dots. The normalized spectra 
show that the optical properties of CdSe/ZnS quantum dots were well preserved even after 
encapsulation with liposomes. Figure 2.1 (c, d) are the fluorescence microscopic images of QD-
liposomes and fluorescein (lipid membrane dye)-liposomes. It is evident from these images that 
the QD-liposomes are brighter than fluorescein-liposomes and also had low background noise 
compared to fluorescein-liposomes. Also the photo bleaching of the fluorescein containing 
liposomes can be seen (Figure 2.1d) while the QD-liposomes were pretty stable under light. 
Cryo-transmission electron microscopy was employed to study the structural 
characteristics of the liposome encapsulated quantum dots. The results as depicted in figure 2.2a 
show that the quantum dots are concentrated in the liposome bilayer membrane that are seen as a 
dense bilayer. The microscopic image 2.2b is a control without quantum dots inside the 
liposomal membrane that do not show dense bilayers as QD-liposomes. Also at lower 
concentrations of quantum dots, the structures of the QD-liposomes were almost spherical in 
shape where as at the higher concentration of QDs, some degree of deformation of the vesicle 
structures was observed, visualized as elongated and deformed vesicular structures in the images 
(figure 2.2d). The cryo-TEM results were in agreement with the previous work by Al Jamal et 
al.
29 
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Figure 2.2 Cryo-transmission electron microscopy images of quantum dot containing liposomes 
at 50 nM (a, c), at 500 nM QD concentration (d), and liposomes without quantum dots (b).  
2.4.2. Fabrication of FRET probes. After characterization of QD-liposomes, the complexes 
were used as fluorescence resonance transfer energy based probes to monitor enzyme activity of 
phospholipase A2. The composition of the QD-liposomes in 1:1:0.4 molar ratio of 
DOPC:DOPG:chol provides the negative charge and the unsaturation on the liposome membrane 
that is necessary for phospholipase A2 enzyme activity.  
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Figure 2.3 Emission spectra of QD-NBD-liposome based FRET probes at (a) 0, (b) 1.25, (c) 2.5, 
(d) 5, (e) 10, and (f) 25 μM of NBD C6-HPC lipid molecule concentration. λex: 375nm.  
Quantum dots present in the lipid bilayer will act as donor and the lipid membrane dye 
NBD will act as acceptor. Different concentrations of NBD C6-HPC lipid molecules of final 
concentrations ranging from 0 to 25 μM were incorporated into QD-liposomes and the probes 
were characterized using spectrofluorometer and digital fluorescence microscope. When excited 
at 375 nm, the absorbance minimum of NBD, to avoid direct excitation of NBD, it was observed 
that the fluorescence resonance energy was transferred from the quantum dot emitting at 480 nm 
to the NBD molecule emitting at 540 nm. This result is represented in figure 2.3 as increased 
NBD intensities and decreased QD intensities at increasing concentrations of NBD.  
2.4.3. Enzyme activity of phospholipase A2. FRET based probes were used to monitor the 
enzymatic activity of the phospholipase A2. Phospholipase A2 is an enzyme that hydrolyzes 
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phospholipids into fatty acids and other lipophilic substances. NBD is labeled on the acyl chain 
of phospholipids as shown in scheme 2.1. The enzyme phospholipase A2 specifically recognizes 
the SN2 acyl bond of phospholipids and breaks away NBD from the lipid membrane. As a result 
energy transfer can no longer takes place as demonstrated by a decreased FRET signal.  
 
Scheme 2.1 Schematic representation of QD-liposome based FRET probes for monitoring 
phospholipase A2 enzyme activity.  
Figure 2.4 shows the emission spectra of QD-liposome based FRET probes at increasing 
phospholipase A2 enzyme activities from 0-75 U/mL. The spectra were recorded 30 min after the 
addition of phospholipase A2 to the QD-liposome solution. An increase in the quantum dot 
emission intensities at 480 nm and a decrease in the NBD emission intensities at 540 nm were 
clearly observed, suggesting a significant decrease in the FRET efficiency with increase in 
phospholipase A2.  
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Figure 2.4 Emission spectra of QD-NBD-liposome based FRET probes with 10 μM NBD and at 
increasing phospholipase A2 enzyme activities: (a) 0, (b) 1.5, (c) 7.5, (d) 15, (e) 37.5, and (f) 75 
U/mL. λex: 375nm.   
A non-linear dependence of normalized Fd/Fa on phospholipase A2 was observed where, 
Fd and Fa are the emission intensities of the quantum dot FRET-based probes at 480 nm 
(quantum dot donors) and 540 nm (NBD acceptors) respectively, when excited at 375 nm. Fd/Fa 
values were normalized to (Fd/Fa)0; the ratio of Fd/Fa prior to adding phospholipase A2 to the QD-
liposome solutions. The dependence of FRET signal on phospholipase A2 concentration was 
attributed to the enzymatic cleavage of the phospholipid molecules that release NBD molecules 
from the lipid molecule into the solution. The NBD molecule is hydrophilic in nature and 
preferentially releases into aqueous phase after cleavage decreasing the FRET efficiency.  
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Control experiments were performed with QD-liposomes without NBD labeling and 
NBD-liposomes without quantum dots. Adding phospholipase A2 did not result in a significant 
change of the emission intensities. These measurements ruled out the possibility of nonspecific 
adsorption of phospholipase A2 on quantum dots surface that might alter resulting emission 
intensities. Also the possibility that the decrease in the fluorescence intensity of NBD during 
FRET enzymatic assays resulted from a change in the chemical environment of the NBD 
molecules during the enzymatic cleavage by phospholipase A2 was precluded. 
Figure 2.5 shows the temporal dependence of the ratio Fd/Fa at increasing phospholipase 
A2 enzyme activities ranging from 0 to 75 U/mL (ex: 375 nm). Fd/Fa increases with increase in 
incubation time and with the increase in phospholipase A2 enzyme activity. It was possible to 
detect the enzymatic activity as low as 0.0075 U/mL (PLA2 = 1500 U/mg) in 30 min at room 
temperature. Control experiments using QD-liposome based probes in the absence of 
phospholipase A2 showed almost no changes in the FRET signal which clearly indicate that the 
changes in FRET signals associated with QD-liposome probes are due to the enzymatic activity 
of phospholipase A2. 
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Figure 2.5 Time dependence of QD-NBD-liposome probes with 10 μM NBD and at increasing 
phospholipase A2 enzyme activities: (a) 0, (b) 0.075, (c) 1.5, (d) 15, and (e) 75 U/mL. λex: 
375nm. The ratio Fd/Fa was normalized to (Fd/Fa)0; the ratio of Fd/Fa prior to adding 
phospholipase A2 to the QD-liposome solutions. 
Images 2.6a and 2.6b are the digital fluorescence microscopic images of QD-liposomes 
and QD-liposomes labeled with NBD respectively. QD-liposomes show their characteristic blue 
emission while the QD-liposomes labeled with NBD emit bluish green light due to FRET 
between the quantum dots and NBD molecules. Image 2.6c shows the fluorescence image of the 
quantum dot FRET-based probes 30 min following the addition of 75 U/mL phospholipase A2. It 
was seen that the emission color of the quantum dots turned blue due to enzymatic cleavage of 
the phospholipid molecule that released NBD molecules to the solution and restored the blue 
emission color of the quantum dots. 
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Figure 2.6 Digital fluorescence microscopic images of (a) only QD-liposomes showing blue 
emission (b) QD-NBD-liposomes with 10 μM NBD showing green emission due to FRET 
between quantum dots and NBD (c) QD-NBD-liposome based probes with 10 μM NBD after 
incubating for 30 min with 75 U/mL phospholipase A2 enzyme activity. Emission spectra are 
provided as insets. 
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Figure 2.7 a) Time dependence of Fd/Fa at 75 U/mL of phospholipase A2 activity and increasing 
concentrations of its inhibitor MJ33. (a) control in the absence of phospholipase and inhibitor, 
(b) 50 μg/mL, (c) 1 μg/mL, (d) 0.1 μg/mL, and (e) 0 μg/mL.  b) time dependence of Fd/Fa at 75 
U/mL of phospholipase A2 activity and increasing concentrations of its inhibitor OBAA. (a) 
control in the absence of phospholipase and inhibitor, (b) 125 μg/mL, (c) 50 μg/mL, (d) 25 
μg/mL, and (e) 0 μg/mL.   
a) 
 
b) 
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2.4.4. Screening enzyme inhibitors. The QD-liposome probes were used to screen the inhibition 
efficiencies of two phospholipase A2 inhibitors: 1-hexadecyl-3-(trifluoroethyl)-sn-glycero-2-
phosphomethanol (MJ33) and 3(4octadecyl) benzoylacrylic acid (OBAA). Figure 2.7a shows the 
temporal dependence of the ratio, Fd/Fa of quantum dot based probes with increasing 
concentrations of inhibitor MJ33 from 0 to 50 μg/mL at 75 U/mL of phospholipase A2 activity. 
Figure 2.7b shows the temporal dependence of the ratio Fd/Fa with increasing concentrations of 
OBAA from 0 to 125 μg/mL at 75 U/mL of phospholipase A2 activity. The rate of increase of 
Fd/Fa was found to be dependent on the concentration of the enzyme inhibitors. The trend 
towards decreasing phospholipase A2 enzyme activity with increase in concentrations of enzyme 
inhibitors was observed for both MJ33 as well as OBAA. However, it was seen that the 
inhibition efficiency of MJ33 was higher than the inhibition efficiency of OBAA at 50 μg/mL. 
2.4.5. Advantages offered by QD based FRET probes. The unique feature of this work is the 
platform of liposome encapsulated QDs that can be prepared using commercially available 
substrates. Since the quantum dots are not attached covalently to the phospholipids they do not 
affect the enzyme activity of phospholipase A2. The FRET format enables real time monitoring 
of the enzyme activity. The QD based FRET probes were able to detect the enzyme activity as 
low as 0.0075 U/mL (PLA2 = 1500 U/mg) in 30 min at room temperature which is the best 
detection limit attained so far in comparison to 0.05 U/mL of commercially available detection 
kit. These FRET probes were further used to screen the inhibition efficiencies of PLA2 inhibitors. 
QD based FRET probes allow for multiplexing and screening large number of inhibitors 
simultaneously. The method is also suitable for both kinetic analysis and large-scale screening 
using automated readers for 96-well plates.  
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2.5 Conclusions 
Liposome encapsulated CdSe/ZnS quantum dots have been synthesized successfully 
making the quantum dots water soluble and biocompatible. The optical characterization revealed 
that the properties of quantum dots were well preserved even after encapsulation with liposomes. 
Structural characterization using cryo-TEM was in accordance with previous work showing 
dense bilayers for QDs encapsulated liposomes. Further to fabricate QD liposome based FRET 
probes, NBD bound to acyl chain of phospholipids was incorporated into QD liposomes. These 
complexes were then used as FRET based probes to monitor the enzyme activity of 
phospholipase A2. The FRET signal changes were found to be phospholipase A2 enzyme activity 
dependent. Since the quantum dots were not attached covalently to the phospholipids, they did 
not affect the enzyme activity of phospholipase A2. The probes were able to detect the enzymatic 
activity as low as 0.0075 U/mL (PLA2 = 1500 U/mg) in 30 min. Therefore, the FRET format 
enables real time monitoring of the enzyme activity. Further these FRET probes were also used 
to screen the inhibition efficiencies of two phospholipase A2 inhibitors 1-hexadecyl-3-
(trifluoroethyl)-sn-glycero-2-phosphomethanol and 3(4octadecyl)benzoylacrylic acid. It is also 
possible to multiplex the assay in a 96 well plate and screen a large number of inhibitors 
simultaneously. Thus the developed in vitro bioassay is sensitive, reliable and can be easily 
performed to provide valuable information about phospholipase A2 and its inhibitors to both the 
medical and pharmacological fields. 
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Chapter 3 
 
 
Synthesis and characterization of liposome encapsulating InP/ZnS 
quantum dots 
 
 
3.1 Abstract  
InP quantum dots (QDs) are popular III-V semiconductor nanocrystals, however, studies 
of InP quantum dots are less advanced in comparison to II-VI semiconductor nanocrystals 
because of their difficult synthetic chemistry and low quantum yield. This work for the first time 
focuses on the synthesis and characterization of liposome encapsulated InP/ZnS quantum dots. 
InP/ZnS-liposome complexes were successfully synthesized preserving the integrity of the 
liposomes. A comparative photostability study of InP/ZnS QD-liposomes with 16-
mercaptohexadecanoic acid (MHDA) coated QDs and InP/ZnS QDs showed enhanced stability 
of InP/ZnS QDs after encapsulation. After 60 min of continuous irradiation, the fluorescence 
intensity of InP/ZnS QDs decreased to 57% of the original intensity, whereas MHDA coated 
QDs and InP/ZnS QD-liposomes decreased by only 30% and 27% respectively. Further the 
effect of pH on the emission of InP/ZnS-liposome complexes was also studied, showing only 
10% variation in the PL intensity of InP/ZnS QDs. Thus InP/ZnS-liposomes exhibit greater 
advantages over InP/ZnS quantum dots demonstrating their utility as a potential tool in several 
biological applications such as bioimaging, bioassays and immunoassays. 
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3.2 Introduction 
Quantum dot based probes have received great interest in the last two decades for optical 
imaging of cells, tissues and in bioassays as an alternative to conventional organic flurophores.
1,2
 
The majority of the research has focused on the use of  II/VI luminescent quantum dots such as 
CdSe or CdSe/ZnS as probes in several biological applications.
3-8 
Also there are studies that 
reported the use of CdTe quantum dots for near infrared bioimaging.
9
 Despite several advantages 
offered by II/VI type QDs, complete replacement of organic fluorophores is limited due to 
cytotoxicity associated with the individual ions present in the quantum dots.
10-12
 The limitation is 
overcome by the growth of thick ZnS shell on top of the CdSe or CdTe nanoparticles making 
them less toxic. The ZnS shell inactivates the non-radiative recombination sites on the core 
surface of the quantum dots to improve the quantum yield; it also acts as a barrier preventing the 
contact of CdSe with the surrounding solvent avoiding dissolution. However, the ZnS shell does 
not provide permanent and complete protection; therefore, the quantum dots are not completely 
safe for biological applications.   
The main advantage of III-V semiconductor nanocrystals over II-VI quantum dots is the 
robustness of the covalent bond as opposed to the ionic bond. The more covalent bond is much 
less likely to allow ionization and subsequent dissolution of the ions, making the particles less 
cytotoxic. Among III-V semiconductor materials InP is popular, due to its bulk band gap of 1.35 
eV that enables quantum dots to have photoluminescence emission wavelengths ranging from 
blue to the near infrared. Thus InP quantum dots serve as alternatives to the frequently used 
CdSe quantum dots for several applications including bio-labeling, light emitting devices, 
photovoltaic cells, quantum dot lasers.
1,13-15 
However, quantum yield (QY) of III-V quantum dots 
is less than 1% due to surface traps and dangling bonds in the crystal lattice and high activation 
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barrier for de-trapping as compared to II-VI semiconductors.
16-18 
 Initially the quantum yields of 
InP NCs were improved to 20–40% by HF etching.19 Recently Peng et al reported InP/ZnS core–
shell quantum dots synthesis using fatty amine for which the quantum yields reached up to 
40%.
20
 A one step and one pot  method for the synthesis of highly luminescent InP with QYs of 
up to 30% and InP/ZnS QDs with QYs of up to 60%  was reported by Nann et al.
21
 More 
recently, Reiss et al synthesized InP/ZnS QDs in a single step with quantum  yield up to 70%.
22
 
Liposomes are concentric bilayered vesicles consisting of a hydrophobic phospholipid 
bilayer surrounding a hydrophilic aqueous phase. Liposomes offer exceptional engineering 
ability because of their physicochemical characteristics such as lipid vesicle size, lipid vesicle 
structure and surface versatility that can be easily modified with established methods. Liposomes 
can entrap large amounts of fluorescent nanoparticles while providing high biocompatibility and 
thus enhancing the effectiveness of nanoparticles for detection in vivo and in vitro.
23
 Therefore 
they have been used to encapsulate and deliver oral vaccines as well as anticancer, 
antiinflammatory and hormonal drugs.
24-26
 Recently, research involving the fabrication of 
liposome-quantum dot vesicles gained more importance as a promising tool in nano-
biotechnology. Liposomes and nanoparticles together are used as novel tools extensively in 
pharmacological profile to retain biocompatibility and physio-chemical characteristics of lipid 
bilayer and luminescent characteristics of QDs for therapeutic and diagnostic applications. 
Cationic liposomes were used to deliver non-targeted CdSe/ZnS quantum dots into the cytosol of 
oncogenic brain cells via lipid mediated fusion with the cell membrane.
27
 In another study, 
researchers were able to internalize cationic lipid QDs in human epithelial lung tumor cells in 
vitro and human cervical carcinoma xenografts in vivo and showed that they were able to 
monitor intracellular trafficking inside the cells.
28
 Recently, it was seen that QD-immuno 
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liposomes were capable of tumor cell-targeting, imaging, and drug delivery functions by 
synthesizing QD-immuno liposomes that selectively and efficiently internalized in human 
epidermal growth factor receptor 2 over expressing tumor cells via receptor-mediated 
endocytosis.
29
  Furthermore, Yang et al demonstrated the targeting and imaging ability of folate 
receptor targeted liposomes containing CdTe QDs in the human uterine cervix cancer cell line.
30
 
In the current study, for the first time, liposome encapsulating InP/ZnS quantum dots 
were successfully synthesized. The structure and optical properties were characterized using 
cryogenic transmission electron microscopy, dynamics scattering light measurements and 
spectroflourometry. A comparative photostability study of InP/ZnS QD-liposomes with 16-
mercaptohexadecanoic acid (MHDA) coated QDs and InP/ZnS QDs was performed. Further the 
effects of pH and quantum dot concentration on the emission intensity of QD-liposomes were 
also studied. The results suggest greater advantages of InP/ZnS-liposome complexes than the 
InP/ZnS quantum dots and thus allowing wide range of biological applications such as 
bioimaging, bioassays and immunoassays. 
3.3 Experimental Methods 
3.3.1 Materials and reagents. Indium acetate (99.99%), myristic acid (99%), 1-dodecanethiol 
(98%), 1-octylamine (99%), 1-octadecene (90%), sulfur (99.9%), zinc stearate (90%), methanol 
anhydrous (99.8%), chloroform (99.5%), 16-mercaptohexadecanoic acid, dihexadecyl phosphate, 
cholesterol were purchased from Sigma Aldrich.  Tris(trimethylsilyl)phosphine (P(TMS)3, 95%) 
was purchased from Alfa Aesar. Dimyristoylphospatidylcholine (DMPC) was purchased from 
Avanti Polar Lipids. N-(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-
phospho-ethanolamine triethyl ammonium salt (DHPE-fluorescein) was purchased from 
Invitrogen. All reagents were used as received without further purification.  
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3.3.2 Synthesis of luminescent InP/ZnS quantum dots. InP/ZnS quantum dots were 
synthesized by following the procedure of Peng et al.
20
 Briefly, 0.4 mmol of indium acetate, 1.2 
mmol of myristic acid, and 5ml of octadecene were loaded into a three-neck flask. The mixture 
was heated to 180ºC under argon flow, for 30 min. Then a solution containing 0.2 mmol of 
P(TMS)3 and 2.4 mmol 1-octylamine made in glove box was injected rapidly into the hot 
reaction mixture and allowed 60 min to react. For the growth of ZnS shell, the reaction solution 
was cooled down to 150ºC. Zinc stearate and sulfur precursors were added consecutively to the 
reaction flask with the InP nanocrystals, waiting for 10 min between each injection at 150ºC. 
After that, the temperature was increased to 230ºC for 20 min to allow the growth of the ZnS 
shell. The reaction was cooled down to room temperature and the nanocrystals were precipitated 
with methanol and centrifuged at 4000 rpm for 20 minutes three times.  The precipitate was then 
redispersed in chloroform. 
3.3.3 Encapsulation of InP/ZnS quantum dots into liposomes. A 20 mM lipid stock solution 
was prepared with a 5:4:1 molar ratio of dimyristoylphospatidylcholine, cholesterol, and 
dihexadecyl phosphate in chloroform. This phospholipid composition provides maximum 
structural stability of liposomes stored at room temperature.
31
 The phospholipid solution was 
stored in a sealed vial at -10°C until use. A 100 μL aliquot of the stock solution was added to 100 
μL of 2 μM InP/ZnS quantum dots and dried under nitrogen in a glass vial until all the 
chloroform was removed.  A thin film was formed at the bottom of the glass tubes. 1 mL of 10 
mM pH 7.4 PBS buffer was added to the above formed thin film. The sample was sonicated for 
5-10 minutes and vortexed for 2 minutes resulting in the formation of unilamellar liposomes. 
3.3.4 Fluorescence spectroscopy measurements. Excitation and emission spectra were 
measured using a spectrofluorometer (Molecular Probes, SpetraMax M2), equipped with a with a 
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75-W continuous Xenon arc lamp as a light source. The samples with DHPE-fluorescein were 
excited at 480nm. Samples having QDs were excited at 400nm. Emission scans were measured 
from 450-700nm. 
3.3.5 Digital fluorescence imaging microscopy. Luminescence images were obtained using a 
digital luminescence imaging microscopy system. The system consisted of an inverted 
fluorescence microscope (Olympus IX71) equipped with a 100 W mercury lamp as a light 
source. The fluorescence images were collected via a 20 X microscope objective with numerical 
aperture = 0.5. A filter cube containing a 420 ±10 nm band-pass excitation filter, a 450 nm 
dichroic mirror, and a 480-nm long pass emission filter was used to ensure spectral imaging 
purity.      
 
Scheme 3.1 Schematic illustration of light path through filter cube in an inverted fluorescence 
microscope. 
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Schematic representation of typical light path through filter cube of an inverted 
fluorescence microscope was shown in scheme 3.1. The filter cube consists of three types of 
filters: excitation filter, emission filter and dichromatic beam splitter (dichroic mirror). 
Excitation filter permits only selected wavelengths from the illuminator to pass through on the 
way toward the specimen. Emission filter is designed to suppress or absorb the excitation 
wavelengths and permit only selected emission wavelengths to pass toward the eye or other 
detector. A dichroic mirror is a specialized filter which is designed to efficiently reflect 
excitation wavelengths and pass emission wavelengths. It is positioned in the light path after the 
excitation filter but before the emission filter. Dichroic mirror is oriented at a 45 degree angle to 
the light passing through the excitation filter and at a 45 degree angle to the emission filter as 
illustrated in Scheme 3.1.  
3.3.6 Transmission electron microscopy. Transmission electron microscope images were taken 
on JEOL 2000EX microscope at an accelerating voltage of 200 kV. One drop of InP/ZnS 
quantum dots (emitting at 520 nm) in chloroform solution was deposited on a copper grid 
covered by an amorphous carbon film and allowed to dry overnight. 
3.3.7 Dynamic light scattering measurements. The average particle size and size distribution 
were determined by dynamic light scattering with a Malvern Zetasizer Nano ZS (Malvern 
Instruments Ltd., U.K.) at 25°C. About 0.2 mL of each liposome suspension was diluted with 2.5 
mL of water immediately after preparation. Each experiment was repeated three times. The zeta 
potential was also measured by using a the Zetasizer ZS instrument. Zeta limits ranged from-150 
to 150 V. Strobing parameters were set as follows: strobe delay -1.00, on time 200.00 ms, and off 
time 1.00 ms.  
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3.4 Results and Discussion 
InP/ZnS quantum dots were synthesized as described by Peng et al.
20
 Different sizes of 
InP/ZnS quantum dots with emission maxima ranging from 450 nm to 680 nm were prepared by 
varying the molar ratios of In and P precursors (Figure 3.1).  The synthesized InP/ZnS quantum 
dots were characterized using spectrofluorometer and transmission electron microscopy.  
 
Figure 3.1 Normalized emission spectra of different InP/ZnS quantum dots in chloroform 
emitting from 450nm to 680nm.  
      
Figure 3.2 Transmission electron microscopic images of InP/ZnS QDs emitting at 556 nm. 
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Figure 3.3 (a) EDS spectrum of InP/ZnS QDs showing the individual peaks of In, P, Zn, and S 
elements. (b) elemental analysis showing a molar ratio of 1:0.4 for In: P in InP/ZnS QDs. 
Figure 3.2 shows the transmission electron microscopic images at different 
magnifications of InP/ZnS quantum dots emitting at 556 nm. The corresponding EDS spectrum, 
shown in Figure 3.3 indicates the presence of individual peaks of In, P, Zn, and S elements 
confirming the composition of InP/ZnS quantum dots. Also, elemental analysis confirmed a 
molar ratio of 1:0.4 for In: P in InP/ZnS quantum dots comparable to the starting material ratio of 
In: P 1:0.5. 
InP/ZnS quantum dot encapsulated in liposomes have been successfully prepared DMPC, 
Chol, DP (5:4:1) liposomal bilayer membrane rendering water solubility to the quantum dots. 
(a) 
(b) 
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This phospholipid composition provides maximum structural stability to liposomes stored at 
room temperature. During the encapsulation process, the surface of QDs interacts with 
hydrophobic regions of the liposomes via hydrophobic interactions and the hydrophilic region of 
the liposome is exposed to the water phase. The liposome encapsulated quantum dots were 
further characterized for optical properties using spectroflourometry and digital fluorescence 
imaging microscopy.   
 
Figure 3.4 (a) Emission spectra and (b) normalized emission spectra of InP/ZnS quantum dots in 
chloroform (red) and liposome encapsulated InP/ZnS quantum dots (green) in pH 7.2 PBS buffer 
at the same concentration of quantum dots.  
Figure 3.4 (a, b) are the emission and normalized emission spectra of InP/ZnS quantum 
dots in chloroform and liposome encapsulated InP/ZnS quantum dots in pH 7.2 PBS buffer with 
the same concentration of quantum dots. As quantum dots are surrounded by two different 
solvent environments in TOPO coated QDs and in liposome encapsulated QDs there might be 
some difference in the emission intensities as observed in Figure 3.4a. The normalized spectra 
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show that the optical properties of InP/ZnS quantum dots were well preserved even after 
encapsulation with liposomes.  
The structural characteristics of these InP/ZnS QD-liposomes were studied by dynamic 
light scattering. The mean diameter of these QD-liposomes was found to be 102.7+6.8 nm, 
similar with the liposomes consisting of the equivalent lipids alone (100.9+3.0 nm). In particle 
size analysis system, the polydispersity index is used to describe the spread in particle diameters 
produced in a sample of particles. As the index approaches zero, the size range produced 
becomes narrower. The polydispersity index of the liposomes and QD-liposomes were 0.17+0.04 
and 0.290+0.01 respectively indicating narrow size distribution. The surface charge 
characteristics measured using zeta potential was found to be -30 mV for liposomes and -29 mV 
for QD-liposome vesicles. The measurements thus revealed that the integrity of liposomes was 
well preserved even after incorporation with InP/ZnS quantum dots. 
 
Figure 3.5 Particle size distributions of (a) liposomes and (b) InP/ZnS QD-liposomes.   
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Figure 3.6 (a) Emission spectra, and (b) normalized graph of liposome encapsulated quantum 
dots in PBS pH 7.2 buffer at various concentrations from 0 nM to500 nM of quantum dots.   
The effect of quantum dot concentration on emission intensity of QD-liposomes was 
studied and compared to that of fluorescein-liposomes (Figure 3.6). It was observed that the 
emission intensity of QD-liposomes increased with an increase in concentrations of quantum 
dots from 0 to 500 nM (Figure 3.6a) and the fluorescence intensity plotted as a function of QDs 
concentration showed a linear regression (Figure 3.6b). On the other hand, the emission intensity 
of fluorescein-liposomes increased with increase in concentration of fluorescein from 0-50 μM 
and then decreased (Figure 3.6b insert). This behavior can be attributed to self-quenching of 
fluorescein. 
The photostability of InP/ZnS QD-liposomes was studied and compared with the MHDA 
capped quantum dots and InP/ZnS quantum dots for 60 min. For demonstration of photostability, 
all the samples were illuminated continuously with a mercury lamp of 60 W/cm
2
 for 1 hr.  The 
fluorescence intensity of the InP/ZnS QDs decreased by 57% of the initial intensity (Figure 3.7). 
On the other hand fluorescent intensity of MHDA capped QDs and QD-liposomes decreased to 
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30% and 27% of the initial intensities after 60 min of continuous illumination. This suggests that 
the encapsulation of InP/ZnS QDs into liposomes further enhances the photostability of the 
InP/ZnS quantum dots. 
 
Figure 3.7 Photostability studies of lnP/ZnS quantum dots (♦), 16-mercaptohexadecanoic acid 
(MHDA) coated InP/ZnS QDs (■), and liposome encapsulated InP/ZnS quantum dots (▲) in 
PBS pH 7.2 buffer. 
The effect of pH on the optical properties of InP/ZnS quantum dots encapsulated in 
liposomes as demonstrated in Figure 3.8 showed that the PL intensity of the InP/ZnS quantum 
dots was independent on the pH of the buffer. When changing the pH of the buffer from 4.2 to 
11.2, less than 10% variation in the PL intensity of InP was observed as opposed to ~40% 
variation in PL intensity of InP/ZnS coated with mercaptosuccinic acid reported by Yong et al.
32
  
The bilayer surrounding the quantum dots is believed to have contributed to greater stability of 
QD-liposomes when altering the pH from 4.2 to 11.2.  
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Figure 3.8 InP/ZnS PL intensity dependence on pH.   
3.5 Conclusions 
 For the first time InP/ZnS quantum dots were incorporated into liposomes, making the 
InP/ZnS quantum dots water soluble and biocompatible. The structural characterization of 
InP/ZnS quantum dots demonstrated well preserved integrity of liposomes even after 
incorporation of InP/ZnS quantum dots. The photostability studies of InP/ZnS QD-liposomes 
compared with the MHDA capped quantum dots and InP/ZnS quantum dots showed that indeed 
encapsulation enhanced the photostability of the InP/ZnS quantum dots. The effect of pH on the 
optical properties of InP/ZnS quantum dots showed < 10% variation in the PL intensity of InP as 
opposed to ~40% variation in PL intensity of InP/ZnS coated with mercaptosuccinic acid 
reported previously by Yong et al.
32
 The results show greater advantages of InP/ZnS QD-
liposomes over InP/ZnS quantum dots. The InP/ZnS-liposome complexes thus synthesized will 
find a wide range of biological applications such as bioimaging, bioassays and immunoassays. 
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Thus InP/ZnS-liposome complexes can aid as potential tools in identification and diagnosis of 
several ailments associated with human pathology. 
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Chapter 4 
 
 
CdSe/ZnS quantum dot based immunoassay for simultaneous 
detection of myocardial infarction biomarkers 
 
4.1 Abstract  
Myocardial infarction or heart attack is the leading cause of death worldwide for both 
men and women. Sensitive and selective measurement of cardiac biomarkers is crucial in 
assisting diagnosis of heart attack and in assessing the patients with nondiagnostic 
electrocardiograms. Quantum dot based probes are receiving great attention for optical imaging 
of cells and in bioassays as an alternative to conventional organic fluorophores due to their 
unique size-dependent chemical and physical properties. In the current study quantum dot based 
fluorescence immunoassay was developed for simultaneous detection of the cardiac biomarkers 
troponin T and troponin I. A sandwich immunoassay was performed with capture antibodies 
immobilized on a 96-well plate. After binding targeted biomarkers to capture antibodies, 
detection antibodies conjugated to CdSe/ZnS quantum dots were then bound to the specific 
biomarkers forming a sandwich complex. The results of the assay showed a clear dependence of 
concentrations for both troponin T and I on the fluorescence emission of quantum dots that were 
bound to the detection antibodies. The detection limit for both troponin T and troponin I was 0.1 
pg/mL. No significant cross reactivity was seen between the antibodies and the antigens. The 
multiplex detection method for screening of biomarkers is expected to yield a high throughput 
diagnostic tool for heart attack. 
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4.2 Introduction 
Myocardial infarction (MI) or heart attack is the leading cause of death in both men and 
women worldwide.
1
 Although long step have been taken to reduce the number of deaths,  the 
number of patients is still increasing.
2, 3
 Over several decades, the diagnosis of MI has been 
based on the “two out of three” criteria as defined by World Health Organization, including 
typical chest pain that lasts for more than 20 minutes, changes in electrocardiogram, and increase 
in the serum level of creatine kinase-MB.
4
 The criteria for diagnosis was redefined recently, that 
gave more importance to cardiac biomarkers especially troponins as they are more superior to 
conventional measurement of CK-MB.
5, 6
 Troponin is a complex of three regulatory muscle 
proteins troponin T (TnT), troponin I (TnI), and troponin C (TnC) that play crucial role in muscle 
contraction. Cardiac and skeletal muscles contain both troponin T and I, however the amino acid 
sequences of the proteins are different.
7
 Troponin C is shared by cardiac and skeletal muscles 
and therefore do not exhibit cardiac specificity and is not used in the diagnosis of cardiac injury. 
Under normal conditions troponin T and I levels are very low, but immediately after heart attack 
the concentrations rise rapidly. The release kinetics is within 4-13 hour for both TnT and TnI 
following myocardial damage.
8, 9  
For the first time in 1989 Katus et al described an enzyme immunoassay to detect 
troponin T in human serum.
10 
The troponin T was bound to the solid phase by an affinity-purified 
polyclonal antibody and detected by peroxidase labeled monoclonal antibody using one-step 
sandwich assay. Later the same group developed a much more sensitive enzyme immunoassay, 
using two troponin T-specific monoclonal antibodies with streptavidin-coated polystyrene tubes 
as the solid phase.
11
 Recently Mayilo et al developed a homogenous immunoassay with gold 
nanoparticles as fluorescence quenchers, using this method a detection limit of 0.7 ng/mL  for 
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cTnT was achieved.
12
 The first assay that demonstrated the potential diagnostic specificity of 
troponin I quantification for myocardial infarction was developed by Cummins et al in 1983.
13
 
Currently, several immunoassay methods are available commercially for the detection of 
troponin I and troponin T separately, most of them are based on UV and some of them are based 
on fluorescence.
14-16
 However, the current detection limits of troponin assays do not allow 
demonstration of normal cardiac troponin levels in healthy controls.
17
 Thus lower detection 
limits with improved assay sensitivity and precision are required to improve risk assessment. 
Colloidal semiconductor nanoparticles or quantum dots (QDs) have emerged as a new 
generation fluorescent labels in the two decades for optical imaging of cells, tissues and in 
bioassays as alternatives to conventional organic fluorophores due to their unique optical 
properties.
18-25
 QDs offer advantages like brightness, greater photostability, and broad excitation 
wavelength range, size-tunable narrow and symmetric emission spectrum. More importantly, 
regardless of the excitation wavelength QDs can be excited efficiently at any wavelength shorter 
than the emission peak that will emit the same narrow, symmetric characteristic spectrum. This 
unique property makes it possible to simultaneously detect different emission peaks when 
different sizes of QDs are excited with a single wavelength. QDs have been used as fluorescent 
labels in several applications including multicolor imaging of tissues
26
 and detection of toxins.
27
 
The applications of QDs have also been extended for microorganism detection using multicolor 
detection based immunoassay formats.
28, 29
 Previously it was shown that QDs has exhibited 
superior photostability than traditional organic dyes in detection and has allowed dual color for 
Cryptosporidium parvum and Giardia lamblia.
30
 
In the current study a new method of CdSe/ZnS quantum dot based fluorescence 
immunoassay has been developed for simultaneous detection of the cardiac biomarkers troponin 
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T and troponin I. In the immunoassay the capture antibodies were immobilized on a 96-well 
plate that were later bound to targeted biomarkers. A sandwich complex was formed after 
detection antibodies conjugated to CdSe/ZnS quantum dots were bound to their specific 
biomarkers. The results of the assay showed a clear dependence of troponins concentration on 
the fluorescence emission of quantum dots attached to the detection antibodies. Detecting the 
two biomarkers simultaneously is aimed to yield a high throughput diagnostic tool for heart 
attack. 
4.3 Experimental Methods 
4.3.1 Materials and reagents. Technical grade (90%) trioctylphosphine oxide (TOPO), 
technical grade (90%) trioctylphosphine (TOP), cadmium oxide (99.99%), selenium powder 
(99.5%), lauric acid (98%), technical grade (90%) hexadecylamine (HDA), diethyl zinc (Zn(Et)2) 
solution 1.0 M in heptane, hexamethyldisilathiane ((TMS)2S), methanol anhydrous (99.8%), 
chloroform (99.5%), 16-mercaptohexadecanoic acid (MHDA), tetramethylammonium hydroxide 
pentahydrate, Tween 20, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
sulfo-N-hydroxysulfosuccunimide (sulfo-NHS), and bovine serum albumin (BSA) were 
purchased from Sigma Aldrich. Amine reactive maleic anhydride activated 96 well plates, and 
super block blocking buffer were purchased from Thermo Scientific. Mouse monoclonal cardiac 
troponin T antibody (1C11), mouse monoclonal cardiac troponin I antibody (M18), cardiac 
troponin T protein, cardiac troponin I protein, and creatine kinase-MB protein were purchased 
from Abcam. Mouse monoclonal cardiac troponin T antibody (7e7), and mouse monoclonal 
cardiac troponin I antibody (MF4) were purchased from Santa Cruz biotechnology.  
4.3.2 Synthesis of TOPO capped luminescent quantum dots. TOPO-capped CdSe/ZnS 
quantum dots were prepared following a method first proposed by Peng et al
31 
with a slight 
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modification.
32
 Briefly, 12-13 mg of cadmium oxide and 160-180 mg of lauric acid were mixed 
under nitrogen atmosphere. The mixture was heated in a 100 mL three neck flask to slightly 
above 180°C to fully dissolve the cadmium oxide (clear solution). Then, 2 g of TOPO and 2 g 
HDA were added to the solution with constant stirring. Temperature was raised to 280°C before 
being cooled down slowly. Upon reaching the desirable temperature 80 mg selenium powder 
dissolved in 2 mL solution of TOP was rapidly injected into the solution under vigorous stirring. 
For shell coating, a 2 mL TOP solution containing 250 μL (TMS)2S and 1 mL Zn(Et)2 was 
injected drop-wise into the solution. The reaction mixture was kept at 180°C for one hour before 
it was cooled to room temperature and washed three times with methanol, centrifuged at 4000 
rpm for 10 minutes each, and redispersed in chloroform. The concentration of this solution was 
found to be 1 μM. The solution was stored at room temperature.   
4.3.3 Synthesis of mercaptohexadecanoic acid (MHDA) coated quantum dots.  16-
mercaptohexadecanoic acid coated quantum dots were prepared following a modified procedure 
developed by Bawendi
33
 for the synthesis of lipoic acid capped CdSe/ZnS core-shell quantum 
dots. 25 mg of MHDA was heated up to 70-80°C to dissolve and 3 mL of  1 μM TOPO coated 
quantum dots and 3 mL of chloroform were added and stirred for 2-3 hours at 50-60°C. Then 6 
mL of DI water containing tetramethylammonium hydroxide pentahydrate was added to the 
mixture and stirred for another half hour at room temperature and then allowed to settle down for 
few minutes. This resulted in a two-phase mixture with the aqueous MHDA coated quantum dots 
layer above the organic chloroform layer. The aqueous layer was collected and centrifuged 
several times to remove TOP/TOPO until clear solution was seen. Then the clear suspensions 
were collected and spin dialyzed two times with a cutoff molecular weight of 30000 Da to 
remove the excess MHDA. In each spin dialysis cycle, the sample was centrifuged at 3000 rpm 
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for 20 minutes and washed with DI water. MHDA coated quantum dots were kept at 4°C in DI 
water until used.  
4.3.4 Conjugation of MHDA coated quantum dots with detection antibodies. Conjugation of 
antibodies onto MHDA coated CdSe/ZnS quantum dots was achieved using the classic EDC 
coupling reaction of COOH groups on the surfaces of the MHDA coated quantum dots and NH2 
groups of the antibody. Typically, 0.1 mL of MHDA coated CdSe/ZnS quantum dots, 20 μL of 
30 mg/mL EDC and 20 μL of 30 mg/mL sulfo-NHS were added into a 1.5 mL tube. The mixture 
was vortexed for 15-20 min at room temperature to fully activate free carboxylic acid groups on 
the quantum dots. In this step, semi stable amine-reactive NHS-ester could be synthesized by the 
esterification of the activated carboxylic acid groups on the QDs and hydroxyl groups on the 
sulfo-NHS. 100 μL of detection antibodies was added into the system and was vortexed for at 
least 2 h. The unreacted antibody molecules were removed from the media by centrifugal 
concentrators (cutoff molecular weight: 100 kD). Quantum dots and antibodies were connected 
through strong covalent bonds. The final products were recollected into 10 mM PBS pH 7.4 
buffer containing 0.1% BSA and kept at 4°C. The purified quantum dot-antibody conjugates 
were ready to be used to detect the target antigens. 
4.3.5 Individual fluoroimmunoassays. Fluoroimmunoassays were essentially performed as 
previously described.
34, 35
 Wells of clear microtiter plates were washed three times with 200 μL 
of wash buffer (PBS pH 8.0 buffer containing 0.05% Tween 20). Then, 100 μL of 25 μg/mL 
concentration of capturing antibodies dissolved in 10 mM PBS pH 7.4 buffer were added to the 
plate and incubated overnight at room temperature. The capture solution was discarded and the 
plates were blocked using 200 μL of super block blocking buffer and incubated for one hour at 
room temperature. This quenches the remaining reactive maleic anhydride groups and also 
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blocks left over open sites on the plate surface. The blocking buffer was discarded and the plate 
washed three times with wash buffer. Different concentrations of 100 μL, troponin T or troponin 
I antigens were added to plate wells and incubated for 1 hour at room temperature. Plate wells 
were washed three times with wash buffer to remove the unbound antigens. 100 μL of the 
detection antibodies conjugated to different colored quantum dots were added to the plate wells 
and incubated for one hour at room temperature and the unbound antibodies were removed by 
washing three times with the wash buffer.  
4.3.6 Multiplexing fluoroimmunoassays. Wells of clear microtiter plates were washed three 
times with 200 μL of wash buffer (PBS pH 8.0 buffer containing 0.05% Tween 20). Then, 50 μL 
each of 50 μg/mL concentration of capturing antibodies dissolved in 10 mM PBS pH 7.4 buffer 
were added to the plate and incubated overnight at room temperature. The capture solution was 
discarded and the plates were blocked using 200 μL of super block blocking buffer and incubated 
for one hour at room temperature. The blocking buffer was discarded and the plate washed three 
times with wash buffer. Different concentrations of 50 μL of troponin T and troponin I antigens 
were added to plate wells and incubated for 1 hour at room temperature. Plate wells were washed 
three times with wash buffer to remove the unbound antigens. 50 μL each of the detection 
antibodies conjugated to two different colored quantum dots were added to the plate wells and 
incubated for one hour at room temperature and the unbound antibodies were removed by 
washing three times with the wash buffer.  
4.3.7 Fluorescence spectroscopy measurements. Excitation and emission spectra were 
measured using a spectrofluorometer (SpectraMax M2, Molecular Devices) equipped with a 75 
W continuous xenon arc lamp as a light source. All the samples were excited at 400 nm. 
Emission scans were measured from 450-750 nm. 
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4.3.8 Digital fluorescence imaging microscopy. Luminescence images were obtained using a 
digital inverted fluorescence microscope (Olympus IX71) equipped with a 100 W mercury lamp 
as a light source. The fluorescence images were collected via a 20 X microscope objective with 
numerical aperture = 0.5. A filter cube containing a 380±20 nm band-pass excitation filter, a 425 
nm dichroic mirror, and a 450 nm long pass emission filter was used to ensure spectral imaging 
purity.  Digital point controller (DP72) was used for digital imaging. An exposure time of 100 
ms was typically used to acquire the fluorescence images.  
4.4 Results and Discussion 
TOPO coating of the luminescent CdSe/ZnS quantum dots were first replaced with 16-
mercaptohexadecanoic acid using ligand exchange method. The optical properties of the 
quantum dots were well preserved even after ligand exchange with MHDA. Antibody conjugated 
quantum dots are often used for biological labeling and staining.
36
 Covalent conjugation of 
quantum dots with biomolecules is most commonly based on cross-linking reactions between 
amine and carboxylic acid groups, between amine and sulfhydryl groups, or between aldehyde 
and hydrazide functional groups. Among these methods the amine-carboxylic acid cross-linking 
method is the more prominent one as most proteins contain primary amine and carboxylic acid 
groups and do not need chemical modifications before conjugation. However, some instability of 
the QDs might occur with this technique when chemically modifying the QDs stabilizer cap and 
the cross-reaction of the QD-COOH groups with multiple amines on biomolecules.
37
 To 
overcome this problem, Hu et al studied the key factors influencing the chemical stability of QDs 
and demonstrated a QD-based bioconjugating strategy.
38
 In the current work EDC coupling of 
quantum dots with the different detection antibodies were achieved following their method.        
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Figure 4.1 Fluorescence intensities of two different colored quantum dots (dotted lines) and QD-
detection antibody conjugates (continuous lines) at the same concentration of QDs. 
Figure 4.1 shows the emission spectra of 545 and 615 nm quantum dots before and after 
conjugation with the detection antibodies of troponin T and troponin I respectively. Quantum 
dot-antibody conjugates have shown slight enhancement in the emission intensity of the QDs 
while retaining optical properties of the quantum dots. This enhancement in intensity might be 
due to presence of antibodies layer on the surface of quantum dots. The stability of the QD-
antibody conjugates stored at 4°C temperature was studied over a period of 28 days. The QD-
antibody conjugates have shown very good stability when stored in 10 mM PBS pH 7.4 buffer 
containing 0.1% BSA demonstrated by 5% decrease in the initial fluorescence intensity (Figure 
4.2). 
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Figure 4.2 Normalized fluorescence intensity of QD-antibody conjugates at different days.  
The immunoreaction was performed using sandwich type procedure. Scheme 4.1 shows 
the quantum dot based fluoroimmunoassay protocol used in this work. At first the capture 
antibodies were immobilized on the well plate followed by the addition of blocking buffer to 
block the nonspecific binding sites. The antigens, troponin T or/and troponin I were added that 
bind to their corresponding capture antibodies. The unbound antigens were removed by washing. 
Finally the detection antibodies conjugated to 545 or/and 615 nm quantum dots were added that 
bind to the corresponding antigens forming a sandwich immunocomplex. The fluorescence 
intensities of the quantum dots attached to the immunocomplex were measured for the 
quantification of the antigens troponin T and troponin I.  
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Scheme 4.1 Schematic representation of QD based fluoroimmunoassay principle. 
4.4.1 Optimization of experimental conditions. The immobilization of the capturing antibody 
on well plate is crucial since it is the first step in the immunoassay system. The concentration of 
capture antibody solution in the immobilization determines the amount of antibody immobilized 
on the well plate. Serial concentrations of antibody solution were tested in order to investigate 
the maximum loading of the capturing antibody. The fluorescence intensity of the quantum dots 
present in the immunocomplex was increased with the capture antibody concentrations from 0 to 
25 μg/mL. Further increase of antibody concentration in the immobilization did not improve the 
results (Figure 4.3).  
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Figure 4.3 Immobilization of capturing antibody (anti-TnT) on 96-well plate at 10 ng/mL of 
troponin T protein and 60 minutes of incubation time. λex: 400 nm. 
 
Figure 4.4 Effect of incubation time on capture of antigen on 96-well plate at 25 μg/mL of 
capture antibody and 10 ng/mL of troponin T protein concentration. λex: 400 nm 
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Next, the effect of incubation time for capturing antigen by the capturing antibody on the 
plate was also optimized. As shown in Figure 4.4 the fluorescence intensity was increased with 
increasing the incubation time up to 60 minutes and further increasing in time did not show any 
increase in the emission intensity indicating that 60 minutes incubation time is optimal. Further 
incubation with longer time may destroy the activity of the antigen and might exert an effect on 
the reorganization of quantum dot conjugated detection antibodies with antigen.  
4.4.2 Individual Assays. For each of the two antigens single analyte assays were performed 
initially to ensure the usefulness of QD-antibody pairs in a multicolor multianalyte study. In 
these assays, only the appropriate capture antibody and individual antigens were applied to wells, 
and the emission intensities of single colored QDs that are conjugated to detection antibodies 
will be measured for quantification.  
 
 
Figure 4.5 a) Emission spectra of 545 nm emitting QDs in the immunocomplex at different 
concentrations of troponin T b) relationship between troponin T concentration and the 
fluorescence intensity of the QDs. 
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Figure 4.5a shows the fluorescence emission spectra of 545 nm emitting quantum dots 
that are conjugated to anti-TnT antibodies. The emission intensity increased with increasing 
concentration of troponin T from 0 to 10 ng/mL. There is a linear-log relationship between the 
enhanced intensity of quantum dots and the concentration of troponin T (Figure 4.5b). The 
detection limit is as low as 0.1 pg/mL for the troponin T which is the best detection limit 
achieved so far that allows the demonstration of the troponin T levels even in the healthy normal 
controls. 
 
Figure 4.6 a) Emission spectra of 615 nm emitting QDs in the immunocomplex at different 
concentrations of troponin I b) relationship between troponin I concentration and the 
fluorescence intensity of the QDs. 
Similarly Figure 4.6a is the fluorescence emission spectra of 615 nm emitting quantum 
dots that are conjugated to anti-TnI antibodies. Similar to troponin T the emission intensity 
increased with increasing concentrations of troponin I. Figure 4.6b shows the concentration 
dependence of the emission intensity of the quantum dots. Similar to troponin T the detection 
limit was as low as 0.1 pg/mL for the troponin I.  
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In principle, the specificity of the method depends mainly upon the specificity of the 
monoclonal antibodies. Nevertheless, the selectivity of the method is also affected by the non-
specific binding on well plate, the properties of the proteins, and the nature of the fluorescence 
labels. The specificity of the method was studied to check for any cross reactivity between the 
antigens and antibodies. The experiments involved the addition of anti-troponin T capturing 
antibody to the well plate followed by the addition of four different antigens 1% BSA, troponin 
T, CK-MB, and Troponin I. The anti-troponin T detection antibodies conjugated to 545 nm 
emitting QDs were added to the well plate. The signals of the quantum dots for this experiment 
are represented as green bars in figure 4.7. Similar procedure was performed for troponin I and 
the signals from the 615 nm emitting QDs are represented as red bars in the figure 4.7. Greater 
signal intensities were observed for the specific antigen-antibody conjugates while there is no 
cross reactivity of the antibodies with the other antigens demonstrating the specificity of the 
method. 
 
Figure 4.7 The selectivity of the quantum dot based fluoroimmunoassay method. 
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4.4.3 Multiplexing Assay. A mixture of troponin T and I capture antibodies were coated on the 
plate. After binding of troponin T and I antigens to capture antibodies, the detection antibodies 
conjugated to CdSe/ZnS quantum dots were then bound to the specific biomarkers. The emission 
spectra of both 545 nm and 615 nm QDs are showed in figure 4.8. The fluorescence intensities 
increased with increasing concentrations of troponin T and troponin I indicating dependence of 
the QDs signals on the concentrations of the corresponding antigens.   
 
Figure 4.8 Emission spectra of 545 nm and 615 nm emitting QDs that are bound to different 
concentrations of troponin T and troponin I respectively.  
4.5 Conclusions 
In summary a new protocol has been developed for quantum dot based 
fluoroimmunoassay for simultaneous detection of troponin T and troponin I. MHDA coated 
quantum dots conjugated to detection antibodies have demonstrated greater stability for extended 
period. The experimental conditions optimized to perform individual assays for the detection of 
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troponin T and troponin I have achieved a detection limit of 0.1 pg/mL. The detection limits 
allow the diagnosis of troponin levels in healthy controls. The method was highly specific for the 
biomarkers troponin T and I with no observed cross reactivity. The multiplex assay was 
successful in detection of two biomarkers simultaneously. The experimental results support the 
success of the method in controlled aqueous (buffer) solution. Therefore to further establish the 
applicability of the method in real samples the method has to be verified in PBS buffer with high 
salt concentrations and eventually in serum samples. Despite success in developing new method 
for diagnosis of biomarkers the method also needs improvement in terms of fast response time as 
increased times for onsite analysis of the biomarkers will delay the patient diagnosis and 
treatment. The QD based fluoroimmunoassay developed will thus yield a high throughput 
diagnostic tool for heart attack.       
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Chapter 5 
 
 
Detection of atherosclerosis biomarkers using a CdSe/ZnS quantum 
dot based fluorescence immunoassay 
 
5.1 Abstract  
Atherosclerosis is a chronic inflammatory vascular disease that involves several events at 
each step from early fatty streak lesions to highly dangerous rupture-prone plaque. Plaque 
rupture can lead to debilitating or deadly events such as heart attack and stroke. Simultaneous 
detection of plasma markers of inflammation and plaque instability will improve assessment of 
risk for vascular events. The current study is aimed to develop a QD based fluorescence 
immunoassay for simultaneous detection of plasma markers monocyte chemoattractant protein-1, 
interleukin 15, and interleukin 18 involved in fatty streak and plaque instability. As preliminary 
work experimental conditions were optimized for detection of MCP-1 and IL-15 achieving 
detection limits of 100 pg/mL and 10 pg/mL respectively. The detection limits are comparable to 
currently reported methods. Further a new approach was proposed to incorporate QDs into silica 
beads before binding to the detection antibodies to further improve the detection limits. The 
future prospects for this work are optimization of experimental conditions for third biomarker 
IL-18 and multiplexing the three biomarkers for simultaneous detection. This study thus provides 
preliminary results to yield a reliable method for simultaneous and rapid detection of multiple 
atherosclerosis biomarkers for early diagnosis.  
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5.2 Introduction 
Atherosclerosis is a chronic inflammatory vascular disease that involves several events at 
each step from early fatty streak lesions to highly dangerous rupture-prone plaque.
1
 The principal 
mechanisms of myocardial and cerebral infarctions involve disruption of atherosclerotic plaques 
and the subsequent formation of thrombus or blood clot.
2
 Atherosclerotic plaques are classified 
into two types, stable and susceptible, of which the latter one is more vulnerable to rupture.
3
 A 
vulnerable plaque is characterized by a large lipid-rich core, a thin fibrous cap, and penetration 
by inflammatory cells, such as macrophages.
4
 Thus, to provide the information for early 
treatment and risk assessment the detection of vulnerable plaques becomes clinically important. 
Detection of vulnerable atherosclerotic plaques involved several imaging techniques including 
conventional X-ray contrast angiography, to detect morphological characteristics such as 
stenosis. However, X-ray contrast angiography was not successful in determining whether a 
plaque is stable or vulnerable as both types of plaques cause stenosis.
5
 In addition to 
conventional methods other approaches involving the use of magnetic resonance imaging (MRI) 
have also been developed. These approaches have been successful in discriminating lipid cores, 
fibrous caps, and hemorrhaged lesions.
6-10
 To directly image an atheroma intravascular ultra 
sonography technique are also currently being used.
11-13
 Computed tomography,
14 
and positron 
emission tomography
15
 are the other new techniques used for diagnosis. However all these new 
approaches do not provide information about presence of inflammation which is indicative of a 
vulnerable plaque though the images provide morphological characteristics of the atheroma. 
Recent research have repeatedly shown the use of biomarkers in different stages of 
atherosclerosis like molecular proinflammatory biomarkers, plaque destabilization and plaque 
rupture biomarkers to predict future cardiovascular prevalence not only in healthy individuals, 
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but also in patients with acute coronary syndrome.
16
 Therefore testing patients for several of 
these biomarkers will provide important information useful for predicting future incidence of 
atherosclerosis. In the previous chapter quantum dots based fluoroimmunoassay method has been 
developed for simultaneous detection of heart attack biomarkers, troponin T and troponin I that 
achieved a detection limit of 0.1 pg/mL. The multiplex assay was able to detect two biomarkers 
simultaneously that will yield a high throughput diagnostic tool for heart attack.  
The current study aims at development of QD based fluorescence immunoassay for 
simultaneous detection of three atherosclerosis markers monocyte chemoattractant protein-1 
(MCP-1), interleukin 15 (IL-15), and interleukin 18 (IL-18) that play significant role in two 
important stages of atherosclerosis, fatty streaks and plaque destabilization. MCP-1 is an 
important chemokine whose expression increases in atherosclerotic lesions, particularly in 
macrophage-rich areas.
17, 18 
Interleukin 15 is a biomarker associated with atherosclerosis whose 
expression is found exclusively in fibrolipid and lipid-rich plaques in complex foam cells.
19, 20 
IL-18, is another biomarker and  increased expression of IL-18 is seen in lesions prone to 
rupture, and is localized mainly in plaque macrophages.
21, 22
 Simultaneous detection of plasma 
markers of inflammation and plaque instability will improve risk assessment for vascular events. 
5.3 Experimental Methods 
5.3.1 Materials and reagents. Technical grade (90%) trioctylphosphine oxide (TOPO), 
technical grade (90%) trioctylphosphine (TOP), cadmium oxide (99.99%), selenium powder 
(99.5%), lauric acid (98%), technical grade (90%) hexadecylamine (HDA), diethyl zinc (Zn(Et)2) 
solution 1.0 M in heptane, hexamethyldisilathiane ((TMS)2S), methanol anhydrous (99.8%), 
chloroform (99.5%), 16-mercaptohexadecanoic acid (MHDA), tetramethylammonium hydroxide 
pentahydrate, Tween 20, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
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sulfo-N-hydroxysulfosuccunimide (sulfo-NHS), and bovine serum albumin were purchased from 
Sigma Aldrich. Amine reactive maleic anhydride activated 96 well plates, and super block 
blocking buffer were purchased from Thermo Scientific. Mouse monoclonal IL-15 antibody, 
rabbit polyclonal IL-15 antibody, IL-15 protein, mouse monoclonal MCP-1 antibody, rabbit 
polyclonal MCP-1 antibody, MCP-1 protein were purchased from Abcam. 
5.3.2 Synthesis of TOPO capped luminescent quantum dots. TOPO-capped CdSe/ZnS 
quantum dots were prepared following a method first proposed by Peng et al
23 
with a slight 
modification.
24
 Briefly, 12-13 mg of cadmium oxide and 160-180 mg of lauric acid were mixed 
under nitrogen atmosphere. The mixture was heated in a 100 mL three neck flask to slightly 
above 180°C to fully dissolve the cadmium oxide (clear solution).  Then, 2 g of TOPO and 2 g 
HDA were added to the solution with constant stirring.  Temperature was raised to 280°C before 
being cooled down slowly. Upon reaching the desirable temperature 80 mg selenium powder 
dissolved in 2 mL solution of TOP was rapidly injected into the solution under vigorous stirring. 
For shell coating, a 2 mL TOP solution containing 250 μL (TMS)2S and 1 mL Zn(Et)2 was 
injected drop-wise into the solution. The reaction mixture was kept at 180°C for one hour before 
it was cooled to room temperature, washed three times with methanol, centrifuged at 4000 rpm 
for 10 minutes each, and redispersed in chloroform. The concentration of this solution was found 
to be 1 μM. The solution was stored at room temperature.   
5.3.3 Synthesis of mercaptohexadecanoic acid (MHDA) coated quantum dots. 16-
mercaptohexadecanoic acid coated quantum dots were prepared following a modified procedure 
developed by Bawendi
25
 for the synthesis of lipoic acid capped CdSe/ZnS core-shell quantum 
dots. 25 mg of MHDA was heated up to 70-80°C to dissolve and 3 mL of  1 μM TOPO coated 
quantum dots and 3 mL of chloroform were added and stirred for 2-3 hours at 50-60°C. Then 6 
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mL of DI water containing tetramethylammonium hydroxide pentahydrate was added to the 
mixture and stirred for another half hour at room temperature and then allowed to settle down for 
few minutes. This resulted in a two-phase mixture with the aqueous MHDA coated quantum dots 
layer above the organic chloroform layer. The aqueous layer was collected and centrifuged 
several times to remove TOP/TOPO until clear solution was seen. Then the clear suspensions 
were collected and spin dialyzed two times with a cutoff molecular weight of 30000 Da to 
remove the excess MHDA. In each spin dialysis cycle, the sample was centrifuged at 3000 rpm 
for 20 minutes and washed with DI water. MHDA coated quantum dots were kept at 4°C in DI 
water until used.  
5.3.4 Conjugation of MHDA coated quantum dots with detection antibodies. Conjugation of 
antibodies onto MHDA coated CdSe/ZnS quantum dots was achieved using the classic EDC 
coupling reaction of COOH groups on the surfaces of the MHDA coated quantum dots and NH2 
groups of the antibody. Typically, 0.1 mL of MHDA coated CdSe/ZnS quantum dots, 20 μL of 
30 mg/mL EDC and 20 μL of 30 mg/mL sulfo-NHS were added into a 1.5 mL tube. The mixture 
was vortexed for 15-20 min at room temperature to fully activate free carboxylic acid groups on 
the quantum dots. In this step, semi stable amine-reactive NHS-ester could be synthesized by the 
esterification of the activated carboxylic acid groups on the QDs and hydroxyl groups on the 
sulfo-NHS. 100 μL of detection antibodies was added into the system and was vortexed for at 
least 2 h. The unreacted antibody molecules were removed from the media by centrifugal 
concentrators (cutoff molecular weight: 100 kD). Quantum dots and antibodies were connected 
through strong covalent bonds. The final products were recollected into 10 mM PBS pH 7.4 
buffer containing 0.1% BSA and kept at 4°C. The purified quantum dot-antibody conjugates 
were ready to be used to detect the target antigens. 
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5.3.5 Individual fluoroimmunoassays. Fluoroimmunoassays were essentially performed as 
previously described.
 26, 27
 Wells of clear microtiter plates were washed three times with 200 μL 
of wash buffer (PBS pH 8.0 buffer containing 0.05% Tween 20). Then, 50 μL of different 
concentration of capturing antibodies dissolved in 10 mM PBS pH 7.4 buffer were added to the 
plate and incubated overnight at room temperature. The capture solution was discarded and the 
plates were blocked using 200 μL of super block blocking buffer and incubated for one hour at 
room temperature. This quenches the remaining reactive maleic anhydride groups and also 
blocks left over open sites on the plate surface. The blocking buffer was discarded and the plate 
washed three times with wash buffer. Different concentrations of 50 μL of IL-15 or MCP-1 
antigens were added to plate wells and incubated for 1 hour at room temperature. Plate wells 
were washed three times with wash buffer to remove the unbound antigens. 50 μL of the 
detection antibodies conjugated to different colored quantum dots were added to the plate wells 
and incubated for one hour at room temperature and the unbound antibodies were removed by 
washing three times with the wash buffer.  
5.3.6 Fluorescence spectroscopy measurements. Excitation and emission spectra were 
measured using a spectrofluorometer (SpectraMax M2, Molecular Devices) equipped with a 75 
W continuous xenon arc lamp as a light source. All the samples were excited at 400 nm. 
Emission scans were measured from 450-750 nm. 
5.3.7 Digital fluorescence imaging microscopy. Luminescence images were obtained using a 
digital inverted fluorescence microscope (Olympus IX71) equipped with a 100 W mercury lamp 
as a light source. The fluorescence images were collected via a 20 X microscope objective with 
numerical aperture = 0.5. A filter cube containing a 380±20 nm band-pass excitation filter, a 425 
nm dichroic mirror, and a 450 nm long pass emission filter was used to ensure spectral imaging 
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purity.  Digital point controller (DP72) was used for digital imaging. An exposure time of 100 
ms was typically used to acquire the fluorescence images.  
5.4 Results and Discussion 
A similar method developed in chapter 4 was used to detect atherosclerosis biomarkers. 
16-mercaptohexadecanoic acid was used to replace TOPO coating of the luminescent CdSe/ZnS 
quantum dots to make them water soluble and biocompatible. Figure 5.1 shows the emission 
spectra and normalized emission spectra of TOPO coated quantum dots and MHDA coated 
quantum dots respectively. The optical properties of the quantum dots were well preserved even 
after ligand exchange with MHDA as shown in Figure 5.1b.  
 
Figure 5.1 (a) Emission and (b) normalized emission spectra of TOPO coated quantum dots (red 
line) and MHDA coated quantum dots (green line) at same concentration of quantum dots.  
Antibody conjugated quantum dots are often used for biological labeling and staining.
28
 
The EDC coupling reaction between a carboxylic group and an amine group is the classic 
reaction for bioconjugation of biomolecules (Scheme 5.1). EDC reacts with the carboxylic 
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groups on the MHDA coated QDs and forms an amine reactive O-acylisourea intermediate. This 
intermediate is very susceptible to hydrolysis and hence is unstable and short lived. The desired 
coupling cannot occur if the targeted amine does not find the active carboxylate before 
hydrolysis and this is overcome by adding the sulfo-NHS. The advantage of addition of sulfo-
NHS to the EDC reaction was to increase the stability of the active intermediate by converting it 
to amine reactive sulfo-NHS ester intermediate which reacts with the attacking amine from the 
antibodies. Excess reagent and isourea are formed as byproducts of the cross-linking reaction 
that are water-soluble and can be easily removed by dialysis or filtration.
29
 The QD-antibody 
bioconjugates were found to be stable and their brightness remained the same for a long time 
when stored in a refrigerator at 4°C in the PBS pH 7.4 buffer solution containing 0.1% BSA.   
 
 
Scheme 5.1 Schematic representation of EDC/NHS coupling chemistry.   
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The immunoreaction was performed using sandwich assay. The workflow of quantum dot 
based fluoroimmunoassay is depicted in scheme 5.1. First the capture antibodies were 
immobilized on the well plate followed by blocking buffer to block the nonspecific binding. The 
antigens IL-15 or/and MCP-1 were added that bind to the corresponding capture antibodies and 
the unbound antigens were removed by washing. Finally the detection antibodies conjugated to 
545nm or/and 615 nm quantum dots were added that bind to the corresponding antigens forming 
a sandwich immunocomplex. The fluorescence intensities of the quantum dots attached to the 
immunocomplex were measured for the quantification of the antigens IL-15 and MCP-1.  
 
Scheme 5.2 Schematic representation of QD based fluoroimmunoassay principle. 
The experimental conditions were initially optimized for the detection of two biomarkers 
IL-15 and MCP-1. The effect of incubation time was optimized for capturing antigen by the 
capturing antibody on the plate. The antigens were added at a concentration of 1 ng/mL and 
incubated at 37
o
C for different time intervals. The fluorescence intensity increased with 
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increasing the incubation time for up to 2 hours and further increasing in time did not show any 
increase in the emission intensity suggesting 2 hours as optimal incubation time at 37
o
C. Further 
incubation for longer periods may destroy the activity of the antigen and effect reorganization of 
quantum dots conjugated detection antibodies with antigen.  
.  
Figure 5.2 Effect of incubation time on capture of antigen on 96-well plate at 25 μg/mL of 
capture antibodies and 1 ng/mL of IL-15 (green) and MCP-1 protein (red) concentration. λex: 
400nm. 
The immobilization of the capturing antibody on well plate is crucial since it is the first 
step in the immunoassay. The concentration of capture antibody solution in the immobilization 
determines the amount of antibody immobilized on the well plate. Serial concentrations of 
antibody solution from 0 to 50 μg/mL were tested in order to investigate the maximum loading 
of the capturing antibody. The fluorescence intensity of the quantum dots present in the 
immunocomplex increased with the capture antibody concentrations from 0 to 50 μg/mL for IL-
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15 and from 0 to 10 μg/mL for MCP-1. Further increase in antibody concentration for the 
immobilization did not improve the previously observed fluorescence intensities (Figure 5.3).  
 
Figure 5.3 Immobilization of capturing antibodies on 96-well plate at 1 ng/mL of IL-15 (green) 
and MCP-1 protein (red) and 60 minutes of incubation time. λex: 400 nm. 
Individual analyte assays were done for each of the two antigens, IL-15 and MCP-1 to 
ensure the use of QD-antibody pairs in a multicolor multianalyte study. In these assays, the 
appropriate capture antibody and individual antigens were applied to wells, and the emission 
intensities of single colored QDs that are conjugated to detection antibodies were measured for 
quantification. Figure 5.4a shows the fluorescence emission spectra of 545 nm emitting quantum 
dots that are conjugated to anti-IL15 antibodies. The emission intensity increased with increasing 
concentrations of troponin T from 0 to 10 ng/mL. There is a linear-log relationship between the 
enhanced intensity of quantum dots and the concentrations of IL-15 (Figure 5.4b). It was 
possible to detect as low as 10 pg/mL for IL-15.  
 97 
 
Figure 5.4 a) Emission spectra of 545 nm emitting QDs in the immunocomplex at different 
concentrations of IL-15 protein b) relationship between IL-15 concentration and the fluorescence 
intensity of the QDs. 
 
Figure 5.5 a) Emission spectra of 615 nm emitting QDs in the immunocomplex at different 
concentrations of MCP-1 b) relationship between MCP-1 concentration and the fluorescence 
intensity of the QDs. 
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Similarly, Figure 5.5a is the fluorescence emission spectra of 615 nm emitting quantum 
dots that are conjugated to anti-MCP-1 antibodies. Similar to IL-15 the emission intensity 
increased with increasing concentrations of troponin I. Figure 5.5b shows the concentration 
dependence of the emission intensity of the quantum dots. The detection limit was found to be 
100 pg/mL for the MCP-1. The specificity of the method was studied to check for any cross 
reactivity between the antigens and antibodies. The experiments involved the addition of anti-
IL15 capturing antibody to the well plate followed by the addition of different antigens 1% 
bovine serum albumin (BSA), IL-15, and MCP-1. The anti-IL15 detection antibodies conjugated 
to 545 nm emitting QDs were added to the well plate. The signals of the quantum dots for this 
experiment are represented as green bars in Figure 5.6. Similar procedure was performed for 
MCP-1 and the signals from the 615 nm emitting QDs are represented as red bars in the Figure 
5.6. Greater signal intensities were observed for the specific antigen-antibody conjugates while 
there is no significant cross reactivity of the antibodies with the other antigens demonstrating the 
specificity of the method. 
 
Figure 5.6 The selectivity of the quantum dot based fluoroimmunoassay method. 
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The detection limits achieved in this work for the biomarkers of atherosclerosis though 
were not the best but are comparable to the currently available methods. This can be attributed to 
the low binding affinity of antigen-antibody pairs used in this method. Therefore a new approach 
was proposed to improve the detection limits by incorporating TOPO coated QDs into silica 
beads before binding to the detection antibodies (Scheme 5.3). Incorporation of large number of 
QDs into a single silica bead will not only improve signal intensity but also will help improve 
results even with low binding affinity antigen-antibody pairs. Furthermore, to complete the study 
optimization of IL-18 and multiplexing of the assay have to be done for simultaneous detection 
of the biomarkers. Also the applicability of the method in real samples collected from patients 
has to be established.  
 
 
Scheme 5.3 Schematic representation of QDs incorporated silica bead based fluoroimmunoassay 
principle. 
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5.5 Conclusions 
The overall goal of the current study is to develop quantum dot based fluoroimmunoassay 
for simultaneous detection of three plasma markers MCP-1, IL-15, and IL-18. Current work only 
shows the optimized experimental conditions to perform individual assays for the detection of 
MCP-1 and IL-15. The methods achieved a detection limit of 10 pg/mL for IL-15 and 100 pg/mL 
for MCP-1 respectively. The inability to achieve better detection limits was attributed to low 
binding affinity between the antigen-antibody pairs used in this method. Furthermore, to 
complete the study optimization of IL-18 needs to be done to multiplex the assay for 
simultaneous detection of these biomarkers. In addition a new approach was proposed to 
improve the detection limits of MCP-1, IL-15 including IL-18 utilizing incorporation of quantum 
dots into silica beads that is expected to increase the sensitivity of the method. The multiplex 
assay able to detect three biomarkers simultaneously will be a high throughput diagnostic tool for 
atherosclerosis. Also the applicability of the method in real samples collected from patients has 
to be established. Despite the limitations the preliminary results are encouraging to develop 
reliable method that will see light in the diagnose of atherosclerosis. 
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Chapter 6  
 
 
Summary and Conclusions 
 
Luminescent quantum dots (QDs) have emerged as alternative fluorescent probes over 
the last two decades in several biological and biomedical fields. They exhibit unique photo-
physical properties, such as broad absorption spectra with narrow and symmetrical emission 
peaks, high quantum yield, high photostability, and size dependent luminescence. This 
dissertation focused on development of quantum dot based bioassays for real time monitoring of 
enzyme activity and simultaneous detection of several biomarkers. 
Recently many research labs have developed quantum dot based fluorescence resonance 
energy transfer (FRET)-based assays.
1-3
 Chang et al developed solution based FRET assays 
using QDs as donors and gold nanoparticles (AuNPs) as acceptors for proteolytic activity 
measurements.
4
 Shi et al from our lab have covalently linked molecular fluorescent acceptors to 
the surface of single quantum dots and used the FRET probes for real-time monitoring of 
protease activity in solution.
3
 Most of the developed quantum dot based FRET assays have 
measured the proteolytic activity. In this study, a quantum dot based FRET assay was employed 
for lipase activity measurements. The liposome encapsulated quantum dot based fluorescence 
resonance energy transfer probes were synthesized and characterized to monitor the enzymatic 
activity of phospholipase A2. The unique feature of this work is the platform, quantum dot 
containing liposomes that can be prepared using commercially available substrates. Since the 
quantum dots are not attached covalently to the phospholipids they do not affect the enzyme 
activity of phospholipase A2. The phospholipid bilayer in QD-liposomes was also labeled with 
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acyl NBD fluorophores. The application of molecular fluorophores as acceptors allows 
ratiometric measurement to monitor FRET that results in real time changes in quantum dot and 
fluorescent acceptor emission peaks. The addition of phospholipase A2 to QD-liposomes showed 
changes in FRET signals due to cleavage of SN2-acyl bond and release of NBD fluorophores 
from the membrane. The NBD molecules are hydrophilic in nature and move away from the 
hydrophobic bilayers following PLA2 enzyme cleavage. The changes in FRET signals were 
found to be phospholipase A2 concentration dependent. The QD based FRET probes were able to 
detect the enzyme activity as low as 0.0075 U/ml (PLA2 = 1500 U/mg) in 30 min at room 
temperature which is the best detection limit attained so far in comparison to commercially 
available kits with detection limits up to 0.05 U/mL. Further the FRET probes were also used to 
screen the inhibition efficiencies of two phospholipase A2 inhibitors 1-hexadecyl-3-
(trifluoroethyl)-sn-glycero-2-phosphomethanol and 3(4octadecyl)benzoylacrylic acid. QD based 
FRET probes allow for multiplexing and screening large number of inhibitors simultaneously. 
The method is also suitable for both kinetic analysis and large-scale screening using automated 
readers for 96-well plates. 
Despite several advantages offered by CdSe/ZnS QDs, replacement of organic 
fluorophores is limited due to cytotoxicity associated with the individual ions present in the 
quantum dots.
5, 6
 Recently, focus has been shifted to the synthesis of cadmium free quantum 
dots. InP quantum dots are more appropriate because they are less cytotoxic and have a wide 
emission range from the UV to near infra red region of the electromagnetic spectrum, which 
makes them ideal candidates for in vivo applications as opposed to CdSe quantum dots. 
However, the quantum yield of III-V quantum dots is less than 1% due to surface traps, dangling 
bonds in the crystal lattice and high activation barrier for de-trapping as compared to II-VI 
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semiconductors.
7 
Recently Peng et al reported InP/ZnS core–shell quantum dot synthesis using a 
fatty amine; for this method the quantum yields reached up to 40%.
8
 A one step and one pot  
method for the synthesis of highly luminescent InP with QYs of up to 30% and InP/ZnS QDs 
with QYs of up to 60%  was reported by Nann et al.
9
 More recently, Reiss et al synthesized 
InP/ZnS QDs in a single step with quantum yield up to 70%.
10 
In the current work, InP/ZnS 
quantum dots were incorporated for the first time into liposomes, making the InP/ZnS quantum 
dots water soluble and biocompatible. The structural characterization of InP/ZnS quantum dots 
demonstrated well preserved integrity of liposomes even after incorporation of InP/ZnS quantum 
dots. The photostability studies of InP/ZnS QD-liposomes compared with the MHDA capped 
quantum dots and InP/ZnS quantum dots showed that encapsulation with liposomes enhanced the 
photostability of the InP/ZnS quantum dots. The effect of pH on the optical properties of 
InP/ZnS quantum dots showed only less than 10% variation in the PL intensity of InP as opposed 
to 35% variation in PL intensity of InP/ZnS coated with mercaptosuccinic acid reported 
previously by Yong et al.
11
 The results demonstrated advantages of InP/ZnS QD-liposomes over 
InP/ZnS quantum dots. The InP/ZnS QD-liposome complexes thus synthesized will find a wide 
range of biological applications such as bioimaging, bioassays, and immunoassays. 
Among several unique characteristics one of the most popular features of quantum dots is 
their ability to multiplex. This unique property makes it possible to simultaneously detect 
different emission peaks when different sizes of QDs are excited with a single wavelength. 
Quantum dots have been used in multiplexed assays by several studies by different research 
groups to detect biomolecules such as multiple DNA targets to specific neurotoxins. In the 
current study a new method of CdSe/ZnS quantum dot based fluorescence immunoassay has 
been developed for simultaneous detection of the cardiac biomarkers troponin T and troponin I. 
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Currently, several immunoassay methods are available commercially for the detection of 
troponin I and troponin T separately, most of them are based on UV absorbance, and some of 
them are based on fluorescence.
12-14
 However, the  detection limits of current troponin assays do 
not allow detection of normal cardiac troponin levels in healthy controls.
15
 Thus lower detection 
limits with improved assay sensitivity and precision are required to improve assessment of risk. 
A sandwich immunoassay was performed with capture antibodies immobilized on a 96-well 
plate. After binding targeted biomarkers to capture antibodies, detection antibodies conjugated to 
CdSe/ZnS quantum dots were then bound to the specific biomarkers forming a sandwich 
complex. The experimental conditions optimized to perform individual assays for the detection 
of troponin T and troponin I have achieved a detection limit of 0.1 pg/mL compare to current 
detection limits of 10 pg/mL for troponin T and 22 pg/mL of troponin I. The detection limits 
allows the diagnosis of troponin levels in healthy controls. The method was highly specific for 
the biomarkers troponin T and I with no observed cross reactivity with different antigens 
troponin T, troponin I, 1% bovine serum albumin (BSA), and creatine kinase (CK-MB). The 
multiplex assay was able to detect two biomarkers simultaneously that will yield a high 
throughput diagnostic tool for heart attack. The experimental results support the success of the 
method in controlled aqueous (buffer) solution. Therefore to further establish the applicability of 
the method in real samples the method has to be verified in PBS buffer with high salt 
concentrations and eventually in serum samples. In addition the method also needs improvement 
in terms of fast response time for onsite analysis of the biomarkers that will expedite patient’s 
diagnosis and treatment procedures. 
According to recent United States statistics, the first symptom of atherosclerosis is heart 
attack or sudden cardiac death among the majority of men and women with this disease. This 
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situation is indicative of the lack of diagnostic methods in early stages of atherosclerosis. Recent 
research has shown the presence of biomarkers at different stages of atherosclerosis, such as 
molecular proinflammatory biomarkers, plaque destabilization and plaque rupture biomarkers. 
These markers can help predict future cardiovascular disease not only in healthy individuals, but 
also in patients with acute coronary syndrome. The method described above for the detection of 
heart attack markers was extended to detect atherosclerosis biomarkers. Thus this study aims at 
development of QD based fluorescence immunoassay for simultaneous detection of three 
atherosclerosis markers MCP-1, IL-15, and IL-18 that play significant roles in two important 
stages of atherosclerosis, fatty streaks and plaque destabilization. Current work only shows the 
optimized experimental conditions to perform individual assays for the detection of MCP-1 and 
IL-15. The method was able to detect as low as 100 pg/mL of MCP-1 and 10 pg/mL of IL-15. 
The inability to achieve better detection limits was attributed to low affinity between the antigen-
antibody pairs used in this method. Therefore a new approach was proposed to improve the 
detection limits by incorporating QDs into silica beads before binding to the detection antibodies. 
Incorporation of large number of QDs into a single silica bead will not only improve signal 
intensity but also will help improve results with low affinity antigen-antibody pairs. Furthermore, 
to complete the study optimization of IL-18 and multiplexing of the assay have to be done for 
simultaneous detection of the biomarkers. Also the applicability of the method in real samples 
collected from patients has to be established. Despite the limitations the preliminary results 
support the development of multiplex assay to detect three biomarkers simultaneously that will 
yield reliable, sensitive, efficient methods for diagnosis of atherosclerosis. 
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6.1 Limitations and Future Studies  
Quantum dots have several advantages over organic dyes as fluorescence probes however 
they pose cytotoxicity that limits their applications especially for in vivo studies. Hence there is 
greater inclination of research towards the synthesis of cadmium free QDs in which InP/ZnS 
QDs emerged as highly potential candidates. InP/ZnS QDs were first time incorporated into 
liposomes in this dissertation which not only makes them biocompatible but also have shown to 
exhibit several advantages in comparison to InP/ZnS QDs. In future studies InP/ZnS QD-
liposomes cytotoxicity needs to be verified. Also cellular internalization studies of the QD-
liposomes would be helpful in demonstrating their potential use in cellular applications. Finally 
with their emissions in wide range of wavelengths from blue to near infra red region their 
applicability can be extended to various areas including cellular labeling, microbiology labeling, 
bioassays, and in NIR imaging.  
Quantum dot based immunoassays are promising tools in simultaneous detection of 
several biomarkers that will need improvement for their implementation in clinical diagnostics. 
The first one being no reliable method for the estimation of number of antibodies attached to one 
quantum dot which might lead to failure in discrimination of different samples especially at 
lower concentration ranges. Second one is cytotoxicity; though not a major obstacle in using the 
QDs for in vitro applications may have negative consequences on the lab personnel working with 
QDs in comparison to commercially available immunoassay kits. Replacing the CdSe QDs with 
InP QDs would greatly minimize these negative consequences. Finally the time and labor might 
also be a limiting factor in the QD based fluoroimmunoassays as it involves several 
bioconjugation steps. Taking these into account and the methods developed in this dissertation 
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with further improvisation, the applicability has to be verified in future with serum samples 
collected from the patients for clinical applications.     
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